Strong impulses for national technological development

BioRegions in Germany Strong impulses for national technological development BioRegions in Germany –

RESEARCH The Germany of Tomorrow This publication is distributed free of charge by the German Federal Ministry of Education and Research as part of its public relations work. It is not intended for commercial sale. It may not be used by political parties, candidates or electoral assistants during an election cam- paign. This applies to parliamentary, state assembly and local govern- ment elections as well as to elections to the European Parliament. In particular the distribution of this publication at election events and at the information stands of political parties, as well as the insertion, printing or affixing of party political information, are regarded as Impressum improper use. The distribution of this publication to third parties as a Published by form of campaign publicity is also prohibited. Bundesministerium Regardless of how recipients came into possession of this publication für Bildung und Forschung / and how many copies of it they may have, it may not be used in a man- Federal Ministry of Education and Research (BMBF) ner that may be considered as showing the partisanship of the Federal Publications and Website Division Government in favour of individual political groups, even if not within 11055 Berlin the context of an upcoming election. Orders In writing to the publisher Postfach 30 02 35 53182 Bonn

Or by Phone: +49 (0) 1805 - 262 302 Fax: +49 (0) 1805 - 262 303 (0.12 Euro/min.)

E-Mail: [email protected] Internet: http://www.bmbf.de

Contributions The Bioregions and companies are responsible for the texts of their contributions. If not stated otherwise they also hold the copyrights of the photographs and graphics therein. Photograph on cover: Merck KGaA

Printed by Druckerei Bonn&Fries 57074 Siegen

Berlin 2004

Printed on recycled paper BioRegions in Germany Strong impulses for national technological development

RESEARCH The Germany of Tomorrow Contents

Foreword 5 Introduction 6-9

BioRegions

Schleswig-Holstein 10-11 Mecklenburg-Vorpommern 12-13 Bremen 14-15 Hamburg 16-17 Berlin-Brandenburg 18-19 Lower Saxony 20-21 Saxony-Anhalt 22-23 Saarland/Rhineland-Palatinate 24-25 Jena 26-27 Saxony 28-29 NRW: Bio-Gen-Tec 30 NRW: Life Science Agency 31 Münster 32-33 East Westphalia Lippe 34-35 Ruhr Region 36-37 Cologne/Düsseldorf 38-39 Aachen, Liège, Maastricht 40-41 Hesse: Hessen Biotech 42-43 Frankfurt 44-45 Marburg 46-47 Baden-Wuerttemberg: BIOPRO 48-49 Rhine-Neckar Triangle 50-51 STERN 52-53 Ulm 54-55 Freiburg 56-57 Bavaria: Bayern Innovativ 58-59 Franconia 60-61 Regensburg 62-63 Munich 64-65

Federal state organisations

2 Biotech success stories

Axxima 66 Biofrontera 67 Brain 68 Cellzome 69 DeveloGen 70 Epigenomics 71 Evotec OAI 72 GPC Biotech 73 Jerini 74 MediGene 75 MorphoSys 76 Paion 77 Qiagen 78 Rentschler 79 Scienion 80 SunGene 81 Teraklin 82 Wilex 83

Interim report

Interim Report on Biotechnology Funding 84-87

3 4 Foreword

The life sciences will economy. This mechanism will play a major make their mark on role in structural change in the economy over the 21st century. Our the next few years. understanding of living organisms is The biotechnology regions in Germany have growing rapidly. provided an effective impetus for commercia- Scientific findings and lization. Approximately 25 bioregions with related technological just under 600 biotech companies have been developments offer a revolutionary potential established since the late 1990s, which is for change and entirely new opportunities for quite a respectable achievement from an the solution of many problems in society - international perspective. But these young from fighting diseases which have so far been businesses must mature and gain considered incurable to sustainable and technological and economic strength. And a intelligent production. Trailblazing sufficient number of new businesses must discoveries are being made in biotechnology follow so that the latest findings can be every year. Science magazine rated four included in the economic diffusion process. developments of modern bioscience among the top ten in 2003. The biosciences are a This publication provides an impressive highly complex field of technology which is overview of the development and prospects of developing very dynamically. the biotechnology regions in Germany. Their success is due not least to the mobilization of Biotechnology today is far more than a considerable public funds as well as to the means to gain fundamental knowledge - it is large amounts of private funds that have becoming a central economic factor. been made available. But this does not mean Although impressive scientific successes have that the challenge has been mastered. An been achieved over the past 25 years, the objective of Federal Government policy commercial exploitation of biotechnology is therefore continues to be to help the only just beginning throughout the world, biotechnology regions become stronger and particularly in Germany. Experts estimate partners in the commercialization of this that about 30% of all branches of industry leading technology. will depend on biotechnology in the future. Biotechnology is thus one of the largest growth areas beside information technology. Edelgard Bulmahn Biotechnological innovations will have a Federal Minister of Education and Research major influence on production in many branches including the chemical industry, pharmaceuticals, agriculture and foodstuffs, environmental and power engineering and the services sector. New, knowledge-intensive and valuable products and processes will be made available to our knowledge-based

5 Introduction BioRegions in Germany

Today Germany is a modern base for and practical strategies designed. The bio- biotechnology in Europe. Following a rapid regions, which were selected by an increase in the number of business start-ups independent international jury, have over the last few years during the race to succeeded to a considerable extent in catch up internationally, Germany now holds combining a sound scientific basis, favourable first place in the field of biotechnology. legal framework conditions and an entrepre- Although the young branch began to neurial spirit. The strengthening of the strong encounter financial bottlenecks in 2003, the in the international competition for economic wave of business start-ups should not be development in biotechnology has led to a allowed to slow down. Know-how is change in trend and has made Germany a continuing to force its way into the field of beacon site for genetic engineering and applications. The young biotech companies biotechnology. The measures which have now require funding for the very long-term been introduced are attracting investors, phases of research and development before accelerating licensing procedures for biotech- they can make their first profits. In a number nological plants and their extensions, and of cases young companies need to focus more kindling entrepreneurial spirit in order to intensely on their strengths when expanding create jobs. Over a five-year period from 1997, further. the model regions „Rhineland“, „Munich“ and „Heidelberg“, which were selected from 17 Lasting impulses applicants, and „Jena“, which received a Support for willing entrepreneurs and young special award, received privileged access to biotechnology companies during and special BMBF project funding totalling A 90 following the foundation phase begins with a million. These „starting funds“ enabled the number of competitions initiated by the regions to attract considerably higher private Federal Ministry of Education and Research and public funding. (BMBF), for example BioRegio, BioProfile and BioChance. The amendment to the Law on Novel products, processes and services Genetic Engineering in 1993 and the The „BioProfile“ competition, which was launching of various competitions since the launched in November 1999 within the mid-90s have given lasting impulses to the framework of the Federal Government’s development of biotechnology in Germany. Biotechnology 2000 funding programme, carried on from the experience and results Change in trend gained from the Bio-Regio competition. The launching of the BMBF’s BioRegio „BioProfile“ was also targeted towards those competition in 1995 led to the formation of regions with excellent conditions for national and cross-border economic areas, i.a. translating biotechnological know-how into bio-regions in which integral concepts for new products, production processes and biotechnological research were developed and services. the results introduced on a commercial basis. Emphasis was placed on specialist strengths in Scientific and economic potential were individual forward-looking applications in the brought together, long-term goals defined field of modern biotechnology. These

6 strengths were to be systematically identified companies - depending on how they are and expanded. Special attention was also defined - and is now the European leader in given to applications outside the health this field. Nevertheless, impressive though this sector, e.g. plant biotechnology and nutrition. race to catch up may be, there should be no Of the original 30 applicant regions from illusions about the shortcomings regarding throughout Germany, 20 took part in the the maturity and the size of German decisive selection round. In the course of the companies. Compared with the, on average, selection procedure, the jury singled out three older British and American companies, most regions which had the potential to develop of the German firms have fewer staff, fewer considerable economic strength in modern financial means and fewer products biotechnology applications which they chose approaching market maturity. themselves. The winning regions were Potsdam/Berlin with the profile „Nutrition- Made up for lost ground in basic research related Diseases (Nutrigenomics)“, Since the middle of the last century, Germany Braunschweig/Göttingen/Hanover with the has also made up for lost ground in basic topic „Functional Genomic Analysis“ and research in biotechnology. In the meantime, Stuttgart/Neckar-Alb (STERN Bio-region) with a the large-scale research funding focus on „Regeneration Biology“. Together the organizations, the German Research bio-regions of the BioProfile competition Association and the Max Planck Society, spend received BMBF project funding totalling A 50 approximately one third of their research million. budgets on basic research within the biosciences and biomedicine. Centres for Strong impulses for national technological genetic engineering and molecular-biological development research at universities and within the Max The effects of this competition have been Planck Society, the Helmholtz Association, the considerable. A dynamic innovation process Leibniz Science Association and the has been set in motion in Germany’s regions. Fraunhofer Society have enabled an efficient This has provided strong impulses for national infrastructure for top-class research to emerge technological development. The initiatives in the fields of medicine, health, nutrition, which were aimed at rapidly translating the agriculture, biotechnology and the award-winning know-how of the research environment. Top-class work is once again establishments into biotechnological being performed in individual scientific products, procedures and services have disciplines. It is now a matter of further triggered a wave of young, aspiring expanding strengths in bioscientific and biotechnology start-ups. They have thus biomedical basic research, in international played an important role in a development competition and by means of international, which has made Germany one of the most particularly European, cooperation. efficient places for biotechnology worldwide. In 1995, there were around 70 biotechnology European collaboration companies in Germany. Today, Germany has The approach taken with bio-region funding between 360 and 500 biotechnology will also improve European cooperation.

7 Introduction

Examples such as the rapid development of concerned. The Federal Ministry of Education the „Bio-Valley Upper Rhine“ tri-national and Research will help to effectively support cooperation network involving the Freiburg the process of restructuring the German bio-region and the Swiss and French biotechnology sector by introducing new neighbouring regions of Basle and Alsace, or funding measures for small and medium-sized the German-Swedish-Danish „Bioconvalley“ companies. project, with the bio-region of Greifswald- Rostock as the German partner, are evidence Entering a decisive phase of this. Biotechnology in Germany has now entered a One thing is true of all these developments: decisive phase. The branch needs venture the use of public funding can have nothing capital, proceeds from contract research, and more than a catalytic function and knock-on investors who believe in the commercial idea effect. By providing young entrepreneurs with of young entrepreneurs from the field of a share of the funding needed for high-risk science. However, the market for venture research projects, it is intended to develop the capital is under particular pressure world- emerging German biotechnology sector to wide. The German biotechnology sector is become an internationally competitive branch feeling the effects particularly severely in its of industry and to tap the potential for current set-up phase. It is now especially employment resulting from modern important that investors should quickly regain biotechnology. Decisive, however, is the effect confidence in this sector of the future. Many of public funding on mobilization. This promising innovations in medicine and amounts to one thousand percent in health, the environment, nutrition and individual cases, such as the bio-regions of agriculture depend on developments in Heidelberg and Munich. It is not without biotechnology. The same is also true of reason that these are termed model regions innovations in industrial production. As and provide a good example to other bio- partners of research, many bio-tech regions in Germany. companies have struggled to establish their own place in the market. In collaboration New funding initiatives with other small and medium-sized The Federal Government is determined to enterprises which have already gained further improve the framework conditions for experience on the market or with large biotechnology in Europe and Germany. concerns, they have a realistic chance of Together with information and surviving the consolidation phase. One must communications technology, biotechnology is therefore expect an increase in the number of a „pacemaker for new technologies“. Today, collaborations, mergers and take-overs. biotechnology is already firmly established German biotechnology will emerge stronger and recognized in the development of drugs from the current process of consolidation. and in medicine. The political sector backs biotechnology and is prepared to support this sector during its consolidation phase. Knowledge is forcing its way onto the field of applications. We cannot afford to jeopardize what we have already achieved in this field as far as research, innovation and industry are

8 9 BioRegion Schleswig- Holstein

BioInitiative Nord: Biotechnology in issues being dealt with are of a medical, Schleswig-Holstein botanical, zoological, nutritional or Following the success of the BioRegio agricultural nature. Furthermore, an inter- competition in 1996, the biotechnology disciplinary institute equipped with large- sector in Schleswig-Holstein has developed scale molecular biological apparatus already dynamically. In the last three years alone, exists - the Zentrum für Biochemie und 14 new biotechnology enterprises have been Molekularbiologie (ZBM). The centre also founded, most of them spin-offs from offers biochemical and molecular biological scientific institutes in the federal state. In services to the private sector. total, around 90 enterprises in Schleswig- Holstein have their main focus in the field of To secure a new generation of qualified biotechnology, 34 of which are engaged in scientists, internationally oriented degree R&D. A large number of these enterprises fall courses have recently been created, e.g. the under the category ‘biomedicine’, other degree course ‘Molecular Biotechnology’ at enterprises are active in the plant breeding the Medizinischen Universität Lübeck or the and food industries as well as in the fields of degree course ‘Medical Technology’ at the environmental and marine biotechnology. University of Applied Sciences Lübeck. Biomedical research in Schleswig-Holstein is Schleswig-Holstein has an excellent scientific focused on transplantation medicine, potential based on research carried out at oncology as well as inflammatory and the Christian-Albrechts-Universität Kiel (CAU), degenerative diseases. the Medizinischen Universität Lübeck (MUL) and the Forschungszentrum Borstel (FZB). To support the creation of university spin- The commercialization of this potential will offs, business incubators for young biotech influence the further development of the start-ups have been set up in the immediate biotechnology sector in the federal state vicinity of the region’s universities, e.g. at decisively. An interdisciplinary centre for the Kieler Innovations- und molecular life sciences is presently being Technologiezentrum (KITZ) or at the built at the CAU. The centre will be available Innovationscampus Lübeck (ICL). The to all research groups that have integrated Technologie-Transfer-Zentrale Schleswig- molecular biological techniques into their Holstein plays a central role as a coordinator research projects, irrespective of whether the and consultant regarding questions

10 In addition, Schleswig-Holstein is integrated into the international network ScanBalt together with the federal states of Hamburg and Mecklenburg-Westernpommerania. The joint goal of the collaboration, spanning 11 northern countries in the biotechnology sector, is to strengthen the international competitiveness of the whole Baltic Sea Region and to develop it into one of the world’s leading life sciences regions.

Contact ttz SH - Technologie-Transfer-Zentrale Schleswig-Holstein GmbH Coordination Centre Biotechnology Wittland 10 24109 Kiel concerning the commercialization of research results emerging from the Sabine Thee, Dipl. Biol. (Project Manager) biotechnology sector in Schleswig-Holstein. Phone: (+49) (0) 4 31-5 19 62-72 E-mail: [email protected] Dr. Dorothee Dähnhardt: Bay to Bio e.V is an active support and Phone: (+49) (0) 4 31-5 19 62-85 communication network for the life sciences, E-mail: [email protected] founded jointly by the federal states of Fax: (+49) (0) 4 31-5 19 62-44 Schleswig-Holstein and Hamburg. Web: www.ttzsh.de

11 BioRegion Mecklenburg- Vorpommern

BioCon Valley® - Life Science in environment for innovative biotechnology Mecklenburg-Vorpommern and science culture. Residents of the state of BioCon Valley® is the place to be for Mecklenburg-Vorpommern are very open biotechnology companies and researchers. towards the growing opportunities and new Mecklenburg-Vorpommern is a region in developments in this field. They follow them north-eastern Germany, which is home to a critically, but unbiased. This is why thriving community of nearly 80 approbation procedures according to biotechnology companies, two important German gene technology laws are approved universities (since 1419 and 1456 the oldest very quickly. Better still, funding and support in Northern Europe) and a number of for biotechnology is extremely important to the government of Mecklenburg- Vorpommern. BioCon Valley® certainly has a bright future. Many companies are already making healthy profits. Technology centres for bio-, medical-, and food technologies are operating nearly to full capacity.

International For centuries the region has enjoyed close respected public research institutions. These ties with the Baltic rim states. It is not are flourishing around the scientific cities of surprising that BioCon Valley® is so strongly Rostock, Greifswald, Schwerin, Teterow, integrated into the biotechnology networks Wismar and Neubrandenburg. of the Baltic and Nordic states. Therefore it Fifteen of these companies are part of the was only natural for it to become one of the core of Germany’s high-tech biotechnology driving forces behind ScanBaltTM, the scene, employing some 630 people. network of networks, which brings together Compared to population size, this is more the activities in biotechnology of the North. than in any other German federal state. In It is not only the first meta-bioregion, but the total there are 1 800 people working in the only European biotechnology region that is biotech companies in the state; in addition really capable of competing with the USA. to the 2 000 scientists, who are employed in Green research institutes. The wide open landscape, is home to successful agro-biotechnological companies, The right climate for growth where in the summer the yellow rape fields BioCon Valley® provides a fertile shine on the hills and plains. Reputed

12 research facilities such as the Federal unique bacterial expression systems. Research Institute for Viral Diseases of Traditionally, aquaculture of fish and plant Animals, the Federal Institute for Breeding species, and the diagnosis and control of fish Research of Cultured Plants, or the Research diseases play a major economic role in the Institute for the Biology of Agricultural region. New challenges for marine Animals, are the backbone of scientific biotechnology include biofilms and the research. Many innovative small and medium struggle against biocorrosion in marine sized companies are engaged in highly environments, as well as biological innovative plant and animal breeding degradation caused by pollutants and the methods, as well as in the development of necessary steps and techniques to eliminate effective and environmentally friendly plant pollution. protection products. Making friends Red Discover BioCon Valley® and see for yourself When medical doctors meet plasma its overwhelming potential. physicists and engineers, comprehensive communication networks generate unique and innovative ideas. A result of this is the creation of internationally recognized centres for innovative regenerative medicine and medicine technologies. But also technologies in the areas of transplantation, bone marrow and stem cells, and diabetes technologies belong to the core competences in medical biotechnology research in BioCon Valley®. The development and production of diagnostics, active substances, clinical studies Contact and pharmacology are widespread and BioCon Valley® Initiative Life Science in Mecklenburg-Vorpommern profitable fields of research and work. Dr. Wolfgang Blank Walther-Rathenaustr. 49a Blue D-17489 Greifswald Approximately 1 700 kilometers of the long, Dr. Heinrich Cuypers beautiful and diversified shores of the Baltic Friedrich-Barnewitzstr. 3 Sea border the north of BioCon Valley®. 18119 Rostock Where tourists relax all year round, scientists Greifswald Office are working hard to recover yet undiscovered Phone: +49 (38 34) 51 5 300 natural treasures from the sea. Uniquely Fax: +49 (38 34) 51 5 102 adapted organisms of the largest brackish Rostock Office water sea in the world hold valuable Phone: (+49) (381) 51 96 49 50 resources, such as low and high molecular Fax: (+49) (381) 51 96 49 52 active substances from marine organisms, or E-mail: [email protected] low-temperature adapted enzymes and Web: www.bcv.org

13 BioRegion

Bremen

The biotechnological activities of the German multidisciplinary research net work „Centre state of Bremen which started in 1996 were of Applied Gensensorik“ (CAG) at the based on the integration of gensensorik, University of Bremen. In this virtual centre of HMG-proteins for diagnosis and therapy as competence, about 35 scientists from 13 well as marine bio-techniques. In the mean- different working groups (University of time, other areas like food and agronomy, Bremen, MPI for Marine Microbiology, medical diagnostics, fishery biology, ecology, Institute for Biological Information Systems epidemiology, and environmental tech- (BIBIS), Institute for Applied Beam nologies are also included. Technology (BIAS), Institute for Prevention Research and Social Medicine (BIPS), and In 1996, gensensorik has been chosen as the University of Tübingen) are developing new region’s biotechnological leading project. It concepts for the microarray technology together with partners from the industry. The dynamic of the development of the Bremen genome research - and especially of genome based analytics - is demonstrated by the fact that in the last years more than A 30 million private and public funding could Genotyping of the hepatitis C virus be raised for this topic. refers to the further development of the microarray technology to an integrated and Three years ago, the International University automated system. Most important part of Bremen (IUB) was founded focusing on the gensensor device is the microarray used nanotechnology-based approaches in bio for specific detection of genetic markers. process engineering. Gensensors are being designed to be used in medical diagnostics, in quality control of Since 2001, the BioRegio project has been food- and feed production processes, or in continued as Bioprofile activity which was environmental analytics. The expertise in lead-managed by the Technology Transfer surface chemistry, chip production, system Centre Bremerhaven with the main focus development, bioinformatics and micro „Functional Sea Food: Developmental system technology which is required for the Concept for the Blue Biotechnology in the developmental work is bundled in the Bremen-Weser-Ems Coastal Region“.

14 A milestone in the development of the blue belongs to the topics BIA is in charge of. biotechnology was the opening of the Furthermore, BIA is active in support and Biotechnology Centre Bio-Nord in May 2003 coordination of new foundations and in Bremerhaven. Members of the domiciled settlements (Dr. A. Turkowsky 0421-9600-340, scientific networks are the Alfred Wegener [email protected], www.bia- Institute for Polar and Marine Research bremen.de) (AWI), the Bremerhaven Institute of Food Technology and Bio Process Engineering, the MPI of Marine Microbiology, die University of Bremen and Oldenburg and the Centre for Tropical Marine Ecology (ZMT). The costs for building and equipment of about A 11.7 million have been financed by the „Objective- 2-Programme“ of the European Union and the State of Bremen (www.bio-nord.de).

Additionally, the biotech- nological companies of the region set emphasis on networking: The Association of Bremen Biotechnology Companies, which at present has 14 members, follow the strategy to strengthen biotechnology and the life sciences by building up a real and a virtual communication and information platform. (Dr. M. Wolf, 0421- Opening of the Bremerhaven BioCentre 2208330; [email protected])

The Bremen Innovation Agency GmbH (BIA) is the contact point for innovation on the Contact Bremen state level. BIA implements the Universität Bremen Prof. Dr. Dietmar Blohm topics of the state, initiates new topics and Leobener Straße integrates the activities into the economy of 28359 Bremen the region. BIA is also active in developing Fon: (+49) (0) 4 21-2 18-47 80 new strategies and the promotion of Fax: (+49) (0) 4 21-2 18-75 78 different sectors. Since 2001, biotechnology E-Mail: [email protected]

15 BioRegion

Hamburg

Location description Hormone and Reproduction Research at the Factors such as the existing infrastructure, University of Hamburg), Heinrich-Pette- short traffic routes to the universities and Institut an der Universität Hamburg scientific institutes, a high recreational value (Heinrich-Pette Institute at the University of due to the proximity to the sea make Hamburg), Max-Planck-Gesellschaft (Max- Hamburg an attractive location for the new Planck Society)- Arbeitsgruppen für establishment of biotechnological companies. strukturelle Molekularbiologie (Workgroups In addition, as far as science and research is for structural molecular biology) and the

concerned Hamburg has a considerable European Molecular Laboratory (EMBL) at the potential in biotechnological know-how with DESY. international expertise. Focal points in industry and research Cross-sectional, developable technologies Molecular diagnoses, cell biology, with a promising future such as biocatalysis/biochemical engineering, bioinformatics and nanotechnology are biomechanics. already based locally and are of significance The companies involved in research and for the further development of the region. development or production and services can mainly be allocated to the sectors of Universities medicine as well as pharmacy and cosmetics. University Hamburg, Technical University (TU) Hamburg-Harburg, Institute for Applied Examples of successful and innovative Sciences companies

Participating research institutes Eppendorf AG, Sequenom, Evotec OAI, Bernhard-Nocht-Institut für Tropenmedizin Strathmann Biotech AG, Celltec GmbH, Artus, (Institute for Tropical Medicine), Institut für CCS Cell Culture Service GMBH, Biomol, Hormon- und Fortpflanzungsforschung an AgeLab Pharma GmbH, BioGlobe GmbH, der Universität Hamburg (Institute for Indivumed GmbH, Murinus GmbH.

16 New developments the newly founded Hamburg Innovation ICBio GmbH (HI) is an established transfer facility In July 2002 the initative Innovations in Hamburg. The TuTech and the ttz in Kiel Centrum Biokatalyse (ICBio) (Innovation are represented in the BaytoBio Förderkreis Centre Biocatalysis) was founded. Under the Life Sciences e.V., an information and auspices of ICBio projects supported by the communication forum for the area of Deutsche Bundesstiftung Umwelt (DBU) Northern Germany. (German Federal Environmental Foundation) are networked with one another and aim at Offers for the incubation period establishing biocatalytic procedures and Individual guidance and consulting for products as environmentally friendly location, financing and promotion offered by alternatives to existing chemical processes. the listed transfer facilities. The ICBio is an open research consortium in TuTech-Starterzentrum: which the transfer of knowledge between Centrum für innovative Medizin (CiM); universities and industry is to be promoted. (Centre for Innovative Medicine); The main topics are screening, expression, MediGate GmbH; biochemical engineering, downstream Hamburger Existenzgründungs Programme processing and the production of resources (hep) (Hamburg Programme for Setting up in and active substances. The coordination Business); office can be found in the TUHH and its Innovationsstiftung Hamburg (Innovation primary aim is the establishment of an Foundation Hamburg); international enzyme bank that centrally BioAgency AG; catalogues and files the great diversity of c:channel business services gmbh (c:bs). enzymes available at the universities and makes it available to customers. Offers in the field of venture capital i-Med/NORD GmbH BioAgency AG The coordination of Life Sciences activities in northern Germany and the interdisciplinary focus towards using the expertise available in the region is one of the key functions of the I-Med Nord GmbH. The mission of this institution, which was founded by the Free and Hanseatic City of Hamburg together Contact with the state of Schleswig-Holstein, is to TUHH Technologie GmbH support innovative medicine linking themes Umwelt- und Biotechnologie coming from both medicine, biotechnology Karin Meyer-Pannwitt, Dipl.-Biol. Harburger Schloßstrasse 6-12 and molecular biology. 21079 Hamburg

Offers of consultation and services in the Phone: (+49) (0) 40-7 66 180 72 Fax: (+49) (0) 40-7 66 180 78 transfer of technology E-mail: [email protected] The TUHH-Technologie GmbH (TuTech) with Web: www.tutech.de

17 BioRegion Berlin- Brandenburg

BioTOP Berlin-Brandenburg - important scientific location. Outstanding Biotechnology’s best address research facilities within the region are the Max Delbrück Centre for Molecular Medicine in Berlin-Buch, the Max-Planck Institute for Molecular Genetics, the Resource Centre of the German Human Genome Project, the protein structure factory, the Konrad-Zuse- Zentrum, and the Berlin University Hospital Charité. Numerous spin-offs have emerged from these institutions, which are known world-wide, over the past few years. In the fields of green biotechnology and foods research, the Max-Planck Institute of Molecular Plant Physiology in Golm and the German Institute for Nutrition Research have international standing. In bioinformatics, Over the past few years the bioregion has Berlin is already the leading centre of established itself extremely well on both the expertise within Germany. national and international levels. The regional areas of expertise were Its research facilities and biotech companies distinguished within the frame of the successfully offer innovative services and National Genome Research Network (2 of 5 products for the world market and in doing core fields are located in Berlin, and the so, cover highly future-oriented research region participates in 4 of 5 clinical fields: networks) and in the BioProfile competition. As of today, Berlin-Brandenburg has attained - Genomics and proteomics (humans & a leading position within Germany with 160 plants) biotech companies. The number has doubled - Molecular medicine & clinical research since 1997. Since then, the SMEs have been - Regenerative medicine & tissue engineering able to acquire more than A 500 million in - Biohybrid technologies Venture Capital. - Bioinformatics The number of - Nutrigenomics jobs within the SMEs has tripled Namely in genome and proteome research to approximately and the molecular medicine that is founded 3,000 since 1997. on it, Berlin-Brandenburg is Europe’s most Numerous

18 companies have begun the clinical - Conception and organisation of events development of pharmaceuticals. It is of - Marketing for the economy and science particular importance that the value creation location chain is fully formed, from the molecular - Strategy consulting biological foundations to clinical testing. The Rapid and uncomplicated financing for start- economic profile is completed by 4 inter- ups and expanding companies is offered by national pharmaceutical corporate groups, the BioFinanz Berlin-Brandenburg network CROs and CMOs. with more than 20 banks and VC companies, BioTOP Berlin-Brandenburg, which is active which is co-ordinated by BioTOP. in the areas of networking, company You can find further information, including a founding and financing, technology transfer, database with comprehensive profiles of all regional marketing and business develop- companies and scientific work groups, at ment, was established in 1998 by the www.biotop.de. governments of Berlin and Branden- burg and the Ver- band der Chemi- schen Industrie e.V. to drive the deve- lopment of bio- technology within the region.

In detail, BioTOP’s goals are: - Support for innovative and technology- oriented new foundings - Support for the financing of complex projects Contact - Technology transfer between science and BioTOP Berlin-Brandenburg Dr. Kai Bindseil economy Fasanenstr.3 - Initiation and establishment of research 10623 Berlin associations Phone: +49 30-31 86 22 11 - Support for scientific and economic Fax: +49 30-31 86 22 22 networks E-mail: [email protected] Web: www.biotop.de - Providing information on biotechnology - Mediation among experts from all BioProfile Koordinationsstelle Nutrigenomik disciplines Dr. Ilka Grötzinger Arthur-Scheunert-Allee 114-116 - Support for companies in business 14558 Bergholz-Rehbrücke development and in the area of press and publicity work Phone: +49 33 200 88 385 Fax: +49 33 200 88 398 - Mediation among specialists and E-mail: [email protected] qualification offensives Web: www.nutrigenomik.de

19 BioRegion

Lower Saxony

- 5,000 Scientists and Researchers Hannover, with its School of Medicine (MHH), - High Density of Large Research is an internationally widely recognised Institutions research location for a broad spectrum of - Key Centres for Agriculture and medicine, e.g. endocrinology, stem cell, or Environmental Technology transplantation medicine, with close - Europe’s Largest Biotech Trade Fair - cooperation and partnerships to business and Biotechnica industry. A young company at MHH operates Germany’s largest commercially used clean With a technology basis like this, Nieder- room to cultivate blood stem cells from sachsen (Lower Saxony) is among the largest cancer patients. Following chemotherapy, biotechnology regions in Germany. Certainly those cells are re-implanted and considerably one of the most outstanding strengths of the help to accelerate the patient’s recovery region is health-care research. In the urban process. The European Neuroscience triangle of Braunschweig-Göttingen-Hannover Institute, located at Göttingen, is part of a main focus is set on the specific research Europe-wide network of neurological areas of infection-, neuro- and stem cell research facilities and represents the special biology. Braunschweig is home e.g. of the strengths of Göttingen’s scientific Helmholtz research centre for Infection community. Here scientists study the Research: The German Centre for molecular mechanisms of brain functions Biotechnology Research, GBF. This is where and disruptions. This research will have fundamental research is conducted to broad implications and a wide range of uncover strategies and processes of applications for the treatment of diseases like pathogens for host organisms’ penetration Alzheimer’s and Parkinson’s. and propagation. Scientists at Nieder- sachsen’s biotechnology companies use this In 2001 an initiative of institutes, universities expertise to develop innovative treatment and biotech companies from the urban and diagnostic procedures. triangle Braunschweig-Göttingen-Hannover was one of three „BioProfile“ contest winners announced by the Federal Ministry of Education and Research (BMBF). The Region now receives A 15 million subsidies for research related to functional genomics.

BioRegioN GmbH is a network, marketing and consulting company. Since the beginning in 1996, the BioRegioN initiative

20 financing. The team of BioRegioN GmbH has access to private equity, public funding programmes and will help start-up firms finding the suitable contact and partners. The start-up package includes support in negotiation, presentation training and business coaching. Even when young companies have completed development of their first product, they can still turn to BioRegioN GmbH for help in finding sales and distribution partners, printing product brochures, designing Web sites or organising trade fair exhibitions. In fact, the professional expertise and business know-how has helped some 80 biotech firms with more available from BioRegioN GmbH than 700 employees to get established in experts is an invaluable asset on Niedersachsen. In late 2002, BioRegioN was the road to success. reorganised as a GmbH, a private, limited liability company. Until 2006 this company has a contract with the government of Niedersachsen that comprises consultancy to innovative entrepreneurial start-ups in life sciences. Raising awareness in Germany, Europe and the rest of the world about the excellent science and biotechnology basis of the state of Niedersachsen and to organize a capital fund for supporting seed, start-up and expansion of life science enterprises in the region are further tasks of BioRegioN GmbH. Contact BioRegioN GmbH Vahrenwalder Strasse 7 A team of analysts, management consultants D-30165 Hannover and marketing experts evaluates potential business ideas and develops start-up concepts Phone: (+49) (0) 5 11-93 57-940 Fax: (+49) (0) 5 11-93 57-963 to support a company’s business plan and E-mail: [email protected] will help young companies secure necessary Web: www.bioregion.de

21 BioRegion Saxony- Anhalt

In autumn 2002 the government of BMBF. This regional topic is accompanied by Saxony-Anhalt has initiated a the traditionally existing breeding companies Biotechnology Offensive to strengthen the and all other parts of the value chain. A biotechnology as one of the future programme for a trial cultivation of branches in the economic region of genetically modified plants will be initiated. Mitteldeutschland. In Saxony-Anhalt, the In 1998 the company SunGene GmbH & Co. biotechnological industry and research KGaA was founded as a joint venture are concentrated on two main topics: between BASF Plant Science and the IPK. Its - Plant biotechnology aim is the directed gene regulation in - Drug and target research cultivated plants. Other spin-off’s of the IPK are NovoPlant GmbH (production of 1. Plant Biotechnology and Breeding recombinant immunological products for Research animal breeding by plants) and TraitGenetics Saxony-Anhalt has an outstanding tradition GmbH (diagnostics of molecular markers for in plant breeding, agriculture, food plant breeding). Icon Genetics GmbH in Halle production and plant biotechnology. The is working on new platform technologies for region has therefore an unique potential in plant made pharmaceuticals. Germany. We also have a very strong political commitment which will support us 2. Drug and target research to develop into the leading research and Saxony-Anhalt has international scientific production centres for green biotechnology reputation at the field of drug and target in Germany. research due to the Institute of Biochemistry The important research institutes are the and Biotechnology at the Martin Luther Federal Centre of Breeding Research on University at Halle and the Interdisciplinary Cultivated Plants (BAZ) in Quedlinburg and Scientific Competence Centre Neurosciences the Leibniz Institutes of Plant Genetics and (located in Magdeburg with the Otto von Crop Plant Research (IPK) in Gatersleben and Guericke University and the Leibniz Institute of Plant Biochemistry (IPB) in Halle. of Neurobiology) and the Max Planck The scientific competence in the field of Institute of dynamics of complex technical molecular plant biotechnology, plant Systems in Magdeburg and the Max Planck biochemistry and breeding research led to Research Unit of Enzymology of Protein the winning project „Plant Biotechnology Folding in Halle. Nordharz/Börde - InnoPlanta“ in the BMBF The topics of the drug research in Saxony- competition „InnoRegio“ which was granted Anhalt, which is co-operating with the in autumn 2000 with A 20 million by the industry in two so-called Innovative Cores for

22 Industrial Growth „Pharma MD“ (Magdeburg) 3. Biotechnological Infrastructure and „Recombinant Therapeutic Proteins“ Saxony-Anhalt is provided with good infras- (Halle), are the search for new therapeu- tructural prerequisites for biotechnological tically active substances against Morbus start-up’s: the Bio-Centre Halle (which has Alzheimer, diabetes and neurodegradative been the greatest branch-specific investment diseases. in Saxony-Anhalt with about A 25 million), the Biotech Founder Centre in Gatersleben Some of the most important companies in (especially for plant biotechnology), and the this field are: Centre for Neuroscientific Innovation and - probiodrug AG, Halle (New pharmaceuticals Technology (ZENIT) in Magdeburg. Also, the against diabetes) Chemistry Parks in Leuna and Bitterfeld offer - KeyNeurotek AG, Magdeburg (Research in advantageous conditions for the settlement neurodegenerative diseases) of biotechnological production companies. A - novosom AG, Halle (Liposomes and BioPark will be built in Gatersleben with a nanoparticles for drug delivery) financial volume up to A 35 million and a - Scil Proteins GmbH, Halle (Development and planned area of 12 ha for laboratories, green production of recombinant proteins) houses and fields. - MelTec GmbH, Magdeburg (Proteomics and cellular target identification ) 4. Your Partners - ACGT, Magdeburg (Development of The Government of Saxony-Anhalt has started diagnostic methods for amyloidogenic a great offensive for the development of diseases, like Morbus Alzheimer) biotechnology in Saxony-Anhalt. It should be Good co-operation exists also between the put into practice under the responsibility of biotech companies on the one side and the BIO Mitteldeutschland GmbH especially pharmaceutical companies as Hexal, Bayer, in the areas of acquisition, project manage- esparma, Serumwerk Bernburg or the ment and communication. For the further Impfstoffwerk Dessau-Tornau, on the other development of biotechnological business it side, which are also located in Saxony-Anhalt. is necessary to come in closer co-operation The research activities can be subdivided in with the States of Saxony and Thuringia. two major working cluster: Collaboration is planned in trans-regional - The co-operation project „recombinant marketing (trade fairs and congresses) and in therapeutic proteins“ for the development the education of scientific and technical and implementation of industrial processes personnel. with recombinant micro-organisms for the production of disulfide-bridged proteins Contact with therapeutic applications. BIO Mitteldeutschland GmbH - The co-operation project „Pharma MD“ for Dr. Jens A. Katzek (Geschäftsführung) Weinbergweg 22 the development, production and marketing 06120 Halle/Saale of new drugs for treatment of so far insufficiently curable diseases like allergies, Phone: (+49) (0) 3 45–55 59-8 50 Fax: (+49) (0) 3 45–55 59-8 53 autoimmune diseases and neurodegene- E-mail: [email protected] rative disorders. Web: www.biomitteldeutschland.de

23 BioRegion Saarland Rhineland Palatinate

What happens to the technical articles, bone and vascular participation implants, filters, membranes and food NanoBioNet in the packaging BioProfile Contest? - Nanoparticles as vehicles for drugs, as The Saarland and the components in compounds and paints Rhineland Palatinate - Sensors for medical diagnostics as well as states together with the environmental and food analyses centre of excellence - Methods aimed at the specific modification NanobioNet e.V. took of technical surfaces made from glass, part in the BioProfile Contest. ceramics, metal and plastics for all branches Right from the beginning this project was of industry planed as a network and to be continued after the contest. The network consists of many partners from industry, research and as well from the administration of the two states.

The interdisciplinary field of nanobiotech- nology, which unites the innovation potential of nano- and biotechnology, makes it possible to establish new methods for developing physiologically safe and biocompatible materials and/or surfaces with the help of biomimetic processes. Nanobiotechnology is thus particularly directed towards developing methods and materials that find application in the fields of biology, medicine, medical The NanoBioNet centre of excellence technology, cosmetics and food technology. NanoBioNet is a competent network of In this region you will already find universities, research institutes, clinics, companies, which put their products enterprises and experts from the fields of successfully on the market. technology transfer, patenting, business and financing. A horizontally as well as vertically Some of the applications already available: organised strategy guarantees every stage of - Intelligent materials for improved medico- the value chain is covered, from R & D

24 The objectives of the association are: - the consistent develop- ment of nanobiotech- nology expertise - the national and through to the marketing and distribution of international positioning of the region as a new or improved products. competitive centre of excellence in the field of nanobiotechnology The NanoBioNet e.V. association - accompanying measures to boost the The NanoBioNet e.V. association was founded innovative powers in the fields of nano- and as a platform for developing our region’s biotechnology in our region leading edge in the field of nanobiotech- - active public relations work in order to nology and informing the general public promote information about nanobiotech- about the potential of this new field of nology and create public awareness for this technology. In the executive committee are high-tech sector Representatives from the Saarland and - promoting research and development Rhineland-Palatinate from the fields of - supporting initial and advanced training in science, business and politics. the field of nanobiotechnology

Contact NanoBioNet e.V. Martin Monzel, Dipl. Ing. Biotechnology Geschäftsführung NanoBioNet e.V. Ministerium für Wirtschaft des Saarlandes Gewerbepark Eschberger Weg Gebäude 3 66121 Saarbrücken

Phone: (+49) (0) 6 81-8 41 12-21 Fax: (+49) (0) 6 81-8 41 12-20 E-mail: [email protected] Web: www.nanobionet.de

25 BioRegion

Jena

BioInstruments Made in Thuringia, Companies, is the key player supporting our Germany BioInstruments Industry. Systems for Thuringia, situated in the middle of Germany automated Screening for pharmaceutically is the gate to the Eastern Partners of the active ingredients, devices for the use in Growing Europe. It is famous for its Laser-Scanning-Microscopes and Fluorescence- competence in BioInstruments and Spectrometers set the standard for the BioDevices. Actually the BioInstruments- international competitors all over the world. Cluster consists of 60 Core-Biotech- Companies, 25 Medicine-Technology- The conceptual design of the BioInstruments- Companies, 23 Research- and Public Cluster in Thuringia was done by the Institutions which bear upon Biotechnology. BioRegio Jena Association. It was so They can rely on the substantial support of successful that it convinced the International powerful Financial Partners, Executive Jury of the German Ministry for Education Consultants and Service Providers. The and Research (BMBF). Eventually the BioInstruments-Cluster equates with a BioRegio Jena Association won the special dynamic and innovative Network of Experts vote of the BMBF. It was rewarded with the from Life Sciences and Engineering Sciences. financial support for 30 biotechnology Today Thuringia is the domicile of 3 Max- cooperation projects bringing together Planck-, 3 Fraunhofer-, 2 Leibniz-Institutes industry and research institutions. The plus numerous internationally recognized projects led to new products, which were Research-Organizations. commercialized by 30 new start-up companies. Delivering BioInstruments to Thuringia has got a long tradition in researchers, other Biotechs, and the commercializing results and knowledge from Pharmaceutical Industry, the Biotech-start- Life Sciences. Internationally most famous is ups in Thuringia were able to generate quick Carl Zeiss, who started his first company in returns and gross profit right from the 1846 in Jena. The company was taken over by beginning. Ernst Abbe in 1889. Already in 1884 Abbe had opened up the „Jenaer Glaswerk Schott The BioRegio Jena Association is serving & Co“ together with Otto Schott. Today the the successful cooperation of economy, Carl Zeiss Jena GmbH, accompanied by science, financial partners and the several regional and international industrial government. It is situated in the partners, namely 8 listed Life Science biotechnology melting pot, the Beutenberg

26 Campus. Here, i.e. in the BioInstruments Centre and the Technology & Innovation Park, the new start-up companies are located. The laboratories and offices can be rented as modules enabling a small start-up to grow according to its needs. In close neighbourhood the start-ups find the Carl Zeiss Jena GmbH, the MPI for Chemical Ecology, the MPI for Bio-Geochemistry, the Friedrich-Schiller- University, the Hans-Knöll-Institute for Natural Products Research, the Institute for Molecular Biotechnology, the Institute for Physical High Technology, and the Fraunhofer Institute for Applied Optics & Fine Mechanics. The Beutenberg Campus therefore is an internationally recognized R&D- centre for biotechnology, chemistry, optics and microtechnology. Its main foci are - Individual-oriented Medicine, - Target-oriented Drug Development, - Bioinformatics and - Nanobiotechnology. together with applications from biotechnology The historically grown linkage of different and medicine to create competitive products disciplines enabled important innovations and services through the unification of know-how in the fields of development and application. Contact Thuringia and the BioRegio Jena Association BioRegio Jena e.V. will stay committed to this multidiscipli- Dr. André H.R. Domin narity. The worldwide trend to miniaturization Winzerlaer Str. 2 07745 Jena and automation will help the biotechnology Germany industry to grow and prosper. We will use the existing competences in micro- and nano- Phone: (+49) 36 41-50 86-50 Fax: (+49) 36 41-50 86-55 technology, in toolbuilding, automation E-mail: [email protected] technology, sensors, physics, chemistry, optics Web: www.bioinstrumente-jena.de

27 BioRegion

Saxony

„Biosaxony“ for Successful Biotechnology concentrated on one strong profile. Under the label „biosaxony“, an interna- The emphasis is on medical applications of tionally important biotech cluster is growing. biotechnology. The focal points in both The scientific and economic centres in centres were intentionally set up to be Dresden and Leipzig boast ultra-modern complimentary - Molecular Bioengineering in work spaces, renowned research groups, Dresden and Regenerative Medicine in excellent training and study opportunities Leipzig. In this way, molecular cell biology and a trendsetting infrastructure. The Saxon and biomedicine are integrated with biotech offensive, initiated in 2000 with traditional excellence in materials science, around A 200 million, furnishes strong engineering and clinical research.

Germany’s largest biotech incubator: BIO CITY As with the BIO CITY, the BioInnovationCenter LEIPZIG in Dresden unites science and business under one roof. economic impulses for biotechnology in the In each of the two bio-incubators, Bio-City Free State of Saxony. Leipzig and BioInnovationCenter Dresden, six Infrastructure development and science and biotechnology professorships work on project support builds a strong and active application-oriented research. Three quarters fundament for application-orientated of the 34.000 square meters of space are research and development. No other federal reserved for biotech companies. These bio state invests more financial assistance into centres span the whole innovation cycle from this branch of the future. For this reason, the fundamental to applied research and the Free State of Saxony is one of the few regions development of R&D-intensive products that has demonstrated continued growth within a confined space. Science and since 2000. business under one roof – This is the success story of both incubators. The integration of Two centres, one strength the universities, the close proximity to Max- Right from the outset, biosaxony has Planck-Institutes, university clinics and state

28 providers, form the economic heart of biotechnology in Saxony. The Free State of Saxony embraces the entire value-added chain: from fundamental research to application-oriented development, interdisci- plinary study centres and institutes for clinical studies, as well as the manufacture of biotechnological products and pharmaceutical research and production. As one of Europe’s leading micro-electronic Biosaxony presented companies and institutions locations, Saxony additionally offers branch- at BIO 2003, Washington D.C. overlapping technology platforms, e.g., for nanotechnology and bioengineering. research centres in both cities leads to a fast technology transfer and a rapid translation of research results into entrepreneurial applications.

Biosaxony Sets Standards The development of worldwide excellent achievements in the most important parts of the Life Sciences covers the whole spectrum of biotechnologically relevant resources. An education offensive, Masters Degree programmes and internationally renowned postgraduate programmes ensure the availability of qualified staff. The 45 core companies, and more than 100 additional Close ties to interdisciplinary research: manufacturer and biotechnology service The Max-Bergmann Centre, a cooperation of Gottfried Wilhelm Leibniz Society and the Technical University of Dresden

Contact biosaxony Dr. Ann De Beuckelaer Tatzberg 47-51 01307 Dresden Germany

Phone: (+49) 351 796 51 05 Internationally renowned basic research: Fax: (+49) 351 796 51 10 The Dresden Max-Planck-Institute for Molecular E-mail: [email protected] Cell Biology and Genetics Web: www.biosaxony.com

29 Federal state organisation North Rhine Westphalia

In 1994 personalities from industry, science and politics founded the association Bio-Gen-Tec NRW to promote the responsible use of modern biotechnology. Thanks to this strong initiative public attitude to modern biotechnology could be changed dramatically to the better: A biotech boom started. Bio-Gen-Tec - the one-stop-shop for founders and with access to consulting and financing networks as well as to public grants - was the crucial catalyst for this success that aroused worldwide attention. Winning the BioRegio Competition in 1996 and helping young founders to build up over 90 companies with A 150 million public grants and A 240 million private capital are regarded as outstanding highlights as well as the worldwide positioning of „Biotechnology made in North Rhine Westphalia“.

Public relations work, lobbying and fostering international contacts and partnerships of Bio-Gen- Tec aim at the sustainable growth of North Rhine Westphalia’s biotechnology. The association represents its over 160 members - companies, institutions and personalities of North Rhine Westphalian biotechnology, among them companies like Bayer, Henkel und Qiagen. Bio-Gen-Tec provides presentation platforms like events, booths on international fairs and special partnering occasions especially for SME and offers marketing support for regions (e.g. the BioRiver concept for biotechnology in the Rhineland). Bio-Gen-Tec initiates and supports regional networks. Together with further key players the association works to consolidate the biotech site North Rhine Westphalia.

Members of the Board of Bio-Gen-Tec are: Prof. Dr. Detlev Riesner (Chairman, also chairman of the board of LSA Life Science Agency GmbH), Prof. Dr. Hermann Lübbert (Deputy Chairman), Dr. Gisbert Kley (Treasurer), Hans Bansner and Hartmut Thomas (CEO).

Starting in 2003 most of the services previously provided by Bio-Gen-Tec are offered by the publicly funded LSA Life Science Agency GmbH, founded and equally owned by the initiatives Bio-Gen-Tec NRW e.V., Health Care NRW e.V. and MeTNet NRW e.V..

As in the past Bio-Gen-Tec NRW e.V. continues to be Contact the strong partner of biotechnology in North Rhine Landesinitiative Bio-Gen-Tec NRW e.V. Westphalia. Hartmut Thomas Nattermann Allee 1 50829 Köln

Phone: (+49) (0) 2 21-94 98 24 54 Fax: (+49) (0) 2 21-94 98 24 44 E-mail: [email protected] Web: www.bio-gen-tec-nrw.de

30 The LSA Life Science Agency was founded in December 2002 with the aim of providing the life science industry in North Rhine Westphalia (NRW) with a central consultancy and service partner competent to lead the industry to international success. The LSA GmbH supports research projects and new company set-ups: the Agency arranges state subsidies, provides consultancy services for the set-up of new companies and assists in the search for business partners in the fields of biotechnology, medical technology and pharmaceuticals/health care service. The LSA GmbH initiates collaboration between companies and colleges: as a result of their many contacts to the world of biotechnology, medical technology and pharmaceuticals, the staff of 12 is able to collaborate and constantly exchange information with companies, scientific institutions and those responsible for funding. At the present time the LSA team is working on an interactive project data bank which will list Life Science research projects in NRW. The project data bank will be made available online so that all those searching for partners and/or projects can have access to it. The LSA brings protagonists in contact with each other and carries the mass of information back to the branch: the LSA GmbH, together with the committee of the Pharmaceutical Licence Club Germany (PLCD), has initiated for the very first time an opening of the PLCD conference to certain select biotech companies in spring 2004. The biotech and pharmaceutical atlases will be extended to include a medical technology atlas NRW and combined to form an online Life Science Atlas. The LSA provides information and instructional work: in events such as the series on marketing and the PR forum, the Agency focuses on the needs of small, new and medium-sized Life Science companies. As a result of its contacts to expert and internationally renowned speakers, the Agency contributes to the growth of knowledge on gene technology in Germany. Together with its partners Bio-Gen-Tec NRW and the Max Planck Institute for Plant Breeding Research, the LSA GmbH organized an international congress for green biotechnology in September 2003. Renowned experts from India, South Africa and Switzerland spoke to more than one hundred participants on the subject „Green Biotechnology & Global Responsibility“ and provided the public debate on green biotechnology with „scientific value“. The LSA GmbH takes part in international fairs: not only does the LSA GmbH provide a place for the business location NRW on the international market with its joint company stands in the main Life Science regions of the world, but also gives new and small companies the opportunity of making Kontakt their developments accessible to a global audience of LSA Life Science Agency GmbH experts. Its collaborative work with the state of NRW Dr. Sylvia Deutschmann Merowingerplatz 1 enables the LSA GmbH to provide companies from the 40225 Düsseldorf branch with access to political decision-makers. The LSA GmbH coalesces the experience and expertise of the Phone: (+49) (0) 2 11-30 12 36-0 Fax: (+49) (0) 2 11-30 12 36-10 three partner associations Bio-Gen-Tec NRW, Health Care E-mail: [email protected] NRW and MeTNet NRW. Web: www.liscia.de

31 BioRegion

Münster

Münster - where Nanotechnology meets - the Interdisciplinary Centre of Electron Life Science Microscopy The focus „nanobioanalytics“ of the - the Max-Planck Institute for Vascular Bioregion Münster is based on the unique Biology combination of exceptional competence in - the Centre for the Molecular Biology of high resolution analysis (electron microscopy, Inflammation (ZMBE) mass spectrometry, near field probes) with - the Interdisciplinary Centre of Clinical top bio-medical research at the University of Research (IZKF) Münster, the University of Applied Science Münster and the 30 local companies. Embedding of these research centres in the Innovations in nanobioanalytics are Biotechnology-Campus with an optimal especially supported by eight interdisci- infrastructure for set-up and growth of plinary research centres: companies fosters the effective transfer of innovations into economic utilization. Special - the Centre for Nanotechnology (CeNTech) facilities are: - the National Expert Centre for - the Technologiehof Münster, which provides Nanoanalytics (Kompetenzzentrum für 10,000 square meters of laboratory space Nanoanalytik) and offices for new companies, counseling - the German-Chinese Centre for Nanoscience and services, - the Laser Centre of the University of - the Technologiepark Münster, which Applied Sciences provides 66,000 square meters with developed property and large office and laboratory space for expanding companies, - the Biotechnology Centre (bioZ) Münster with specialized laboratory space (S1) for growing biotech companies, - the Centre for Nanotechnology (CeNTech), which provides 2,500 square meters of specialized laboratory space for nanobioana- lytical research being performed by university groups and companies, - the EUREGIO Biotechnology Centre, which provides laboratory space, equipment and scientific personnel for biotechnology start- up companies,

32 Zentren der Münsteraner Nanobioanalytik Nanoanalytik The research centres, companies and public

CeNTech business development corporations joint Kompetenzzentrum Nanoanalytik Deutsch-Chinesisches Zentrum für Nanowissenschaften forces and founded the association Interdisziplinäres Zentrum für Elektronenmikroskopie bioanalytik-muenster to co-ordinate activities Nano- Interdis- ziplinäres of all partners and to provide a central Anorganisch-. Zentrum für Chemisches bioanalytik Klinische Institut information and communication platform of Münster Forschung (IZKF) the region. Due to the mutual efforts of all Institut für Zentrum für Chemo- und Molekularbiologie Biosensorik der Entzündung partners and the focus on nanobioanalytics Sensorik (ZMBE) Medizin Münster today ranks among the leading MPI für Vaskuläre Biologie nanobiotechnology locations in Europe. This top level position is emphasised by the co- According to the main research areas of the leadership of the EC Network of Excellence research centres most biotech companies „Nanao2Life“. This network will structure and offer analytical and diagnostic products and integrate the European nanobiotechnology services for medical and environmental research area into a future European applications. The spectrum ranges from Institute of Nanobiotechnology within the microbiological and (bio)chemical analysis to next four years. bio-chips and production of natural or synthetic compounds. A unique selling point for Münster is the increasing cross-linkage and cooperation between the life-science- SMEs and companies, which sell products and services for high resolution nanoanalytics using mass spectrometry and near field probes.

Supply of highly qualified work force is guaranteed by the more than 5000 students enrolled in the life science and biomedical study courses at the University of Münster and the engineer courses at the University of Applied Sciences Münster. In addition, the special biotechnology study course, the International Graduate School of Chemistry, Contact the institute for „Business Management in bioanalytik-muenster Chemistry and the „Institute for PD Dr. Klaus-Michael Weltring Mendelstr. 11 Entrepreneurship and Business development“ D-48149 Münster provide necessary management skills beside the scientific education and thereby ensure Phone: (+49) (0) 2 51-9 80 12-12 Fax: (+49) (0) 2 51-9 80 12-13 the commercial development of the E-mail: [email protected] nanobioanalytics location Münster. Web: www.bioanalytik-muenster.de

33 BioRegion East Westphalia Lippe

The Region of East Westphalia Lippe (Ost- core biotech westfalen-Lippe, OWL) concentrates on its companies. They deal strength: the recently established with pharmaceutical association „Bio-Tech-Region OstWestfalen and molecular Lippe e.V.“(www.bio-owl.de) pursues the biotechnology, following goals: bioinformatics and genome-research, - Establishment of a network of local biotech fermentation and cell companies culture technology, - Improvement of cooperation between seed breeding and science and economy food technology. - Public relations work to improve the image Additionally, there is Source: Girindus AG of biotechnology a huge number of suppliers, i.e. laboratory - Supporting new business set-ups equipment, consumables and filling - Creation of structures to assist young machines. Due to its high economic power biotech companies and to intensify the the food processing industry in OWL is the exchange of experiences most important partner of biotech-companies outside the core industry. As a user of At present, there are about 30 to 40 firms biotechnological processes it is a cooperation with altogether 300-500 employees in the partner and likewise important customer in the field of analytics and process technology. By means of „Sprungbrett OWL“ - an institution that provides assistance in expanding business contacts for young companies - cooperation between firms in the area of quality assurance and qualification has been established.

The University of Bielefeld and the University of Applied Science in Lippe and Höxter enjoy brilliant international reputation, among others because of their activities in genome research resp. food technology. In Bielefeld, excellent focal points are Source: Girindus AG

34 Agricultural economics, Laboratory for Biotechnology and Quality Assurance, Technical Chemistry and Chemical Process technology), the University of Applied Sciences Lippe and Höxter (Faculty of Food technology with focus on microbiology, biochemistry, biotechnology and pharmaceutical technology), the University of Applied Sciences Bielefeld and the Federal Research Centre for Nutrition and Food in Detmold. Research areas of the latter Source: Girindus AG institution are the processing of renewable raw materials on the basis of starch, research projects in the field of innovative nutrition with high physiological bioinformatics and genome research of value, the utilization of protein-rich residues micro organism. The University of Bielefeld as additives in nutrition and the selection offers Cell and Molecular Biology, and modifying of starter cultures. Bioinformatics and Genome Research, Plant Physiology and Molecular Biotechnology as well as Fermentation and Cell Culture Technology on a qualitatively very high level. The Centre of Biotechnology (CeBiTec) combines interdisciplinary research activities at the Institutes of Bioinformatics and Genome Research, the „Bioinformatic Resource facility“, and the „International Source: Syngenta Seeds GmbH Graduate School in Bioinformatics and Kontakt Genome Research“. Also the „Institute of Bio-Tech-Region OstWestfalenLippe e.V. Science and Technology Research“ (IWT) for Technologiezentrum Bielefeld their engineering results assessment in the Erika Sahrhage Meisenstraße 96 area of bio- and gene technology as well as 33607 Bielefeld the expertise of the faculty of Public Health enjoy international reputation. Phone: (+49) (0) 5 21-29 97-470 Fax: (+49) (0) 5 21-29 97-101 This excellent scientific basic is completed by E-mail: [email protected] the University of Paderborn (Faculty of Web: www.bio-owl.de

35 BioRegion

Ruhr Region

Network for Life Technologies in the Ruhr Life Technologies Ruhr - under this umbrella Region trademark, we have combined the fields of biomedical and medical technology and Life Technologies Ruhr - is your bio- biotechnology in a region which many still technology pool in the metropolitan Ruhr identify with its mining industry past. Yet region where two experienced partners, today, this region is now home to the most BioIndustry and BioMedTec Ruhr, have joined concentrated hospital landscape in all of to form a powerful combination of core Europe, with over 130 hospitals with a competences and know-how through capacity of over 50,000 beds and employing networking. Our team have lined up to over 80,000 professionals and workers. Life lastingly reinforce the potentials of medical Technologies thus offers a vast market which technology and biotechnology in the Ruhr is closely linked with the most important region. We provide a contact basis for concerns of today in medical, engineering companies, science and new business and scientific research. endeavors. The quality and scope of the parties involved speak for themselves: more It is Life Technologies Ruhr’s objective to than 50 companies are now part of Life capitalize on the clinical and scientific Technologies Ruhr, as well as the universities strengths of the Ruhr region, capitalize in in the Ruhr region and other institutes and every meaning of this particular word public institutions. Our support comes from towards further technology-oriented the highest levels - from the state of North company developments. Towards this end, we Rhine-Westphalia through its Department of are making available an integrated and Science, the Department of Commerce and viable programme of development made up the Projekt Ruhr GmbH. of the following components: - The development of locations in which the state of North Rhine-Westphalia and the municipalities of the Ruhr region will invest more than A 50 million through 2008 to bundle technology-oriented companies in the neighbourhood of the universities; - the realisation of technology projects by innovative companies which can then be further promoted by means of technology and settlement strategies and through mobilisation of external and equity capital;

36 - further contouring of product families Life Technologies Ruhr offers a broad which will enable Life Technologies Ruhr to catalogue of services: capture leading positions in the market of - Qualified information on research technological products and services, institutions of the region according to a ten-year plan of - Initiation of scientific cooperation and development. mediation of company partners - Consulting for start-ups and new businesses Life Technologies Ruhr - our work foundations programme is tailored to meet the needs of - Support any new company or institute which would - for settlements like to become part of the team of the line- - for development funds acquisition up of existing companies and research - during acquisition of venture capital institutions and to participate in and benefit - in licensing and contract negotiations from their experience and knowledge. - in the protection of industrial property The following specialized areas of research - rights and development provide an overview of the - in marketing and sales current research interests that make up the - in trade show appearance and PR-work Life Technologies: - CRO (contract research office) - Biomaterials - Initiating of training, further education and - Bio-IT qualification. - BioMEMS - Bioprocessing - Imaging - Proteomics - Medical-IT - Operation Procedures

In order to convert this goal into reality, the initiative has developed a broad catalogue of services, with its headquarter at the campus of the Ruhr-University in Bochum. These are specifically tailored to innovative companies which are looking to become efficient business models in the life sciences. Life Technologies Ruhr assesses the economic Contact importance of main areas of research and BioIndustry e.V. innovation at the universities and in their Dr. Frank Eiden Ernst-Schering-Str. 14 environment. Companies and institutes 59192 Bergkamen cooperate with Life Technologies Ruhr as networkers in order to profile the Life Tech- Phone: (+49) (0) 234 97836 50 Telafax: (+49) (0) 0234 97836 14 nologies of the Ruhr region in biotechnology E-mail: [email protected] on the basis of their combined know-how. Web: www.bioindustry.de

37 BioRegion Cologne/ Düsseldorf

The river Rhine - connecting the cities of Düsseldorf, Cologne, Bonn, Aachen and Cologne and Düsseldorf - named the core Jülich. They provide an environment that region of North Rhine Westphalia’s bio- fosters internationally competitive research technology: BioRiver®. About three quarters and forward-looking ideas jointly presented of the more than 300 biotech companies in as BioRiver Science. North Rhine Westphalia are concentrated Biotech incubators have been formed in close around the cities of Cologne, Düsseldorf, proximity to universities to improve the tech- Leverkusen, Bonn, Aachen and Jülich. nology transfer process. The Cell Centre Cologne, the BIOcentre Cologne, the Life There is no other BioRegion in Germany that Science Centre Düsseldorf, the MTZ Aachen, offers more jobs, turnover or win in the the Technology Centre Jülich and LIFE & biotech sector than BioRiver®. Just about BRAIN GmbH in Bonn are just a few every modern biotechnology field features examples. 18 technology centres have joined prominently in its research and development forces as BioRiver Parks and provide start-ups activities. Located within Europe’s most with access to a total area of over 200,000 m2, dense network of universities, and supported of which over 70,000 m2 are laboratory space by a well-established chemical and pharma- (www.bioriverparks.de). ceuticals industry - e.g. Henkel, Bayer, The availability of highly qualified Schwarz Pharma or Aventis - BioRiver® offers professionals is another key advantage of excellent opportunities to start-ups in the BioRiver®, for the dense research network of modern biotech scene. over 50 universities also trains top scientists. BioRiver Companies such as Amaxa, Furthermore there are numerous places of Biofrontera, Cardion, Dasgip, Exelixis, training for all the other qualification levels Memorec, Paion, Qiagen and Verigen are needed in the biotech industry - a crucial prime examples of growth and innovation, factor particularly for young companies in and underline the broad scope of the biotech the midst of expansion. sector’s development in North Rhine The world’s highest concentration of Westphalia, with 18 million inhabitants motorways and railways, four international Germany’s most densely populated state. airports and Frankfurt Airport within one The area’s innovative research landscape is hour’s reach from Cologne link BioRiver® characterised by internationally renowned with the world. universities and research institutes in A word on the BioRiver Cities: Attractive and

38 affordable places to live, even on a lower income, almost infinite expansion opportunities for growing biotech companies and last but not least the broad variety of cultural activities and the famous cultural heritage - these factors set BioRiver® apart from other biotech clusters, particularly those concentrated in a small area. Four million inhabitants live within a circle with a radius of less than 23 miles. Together with its outstanding transport infrastructure, this makes BioRiver® compact and accessible.

The key players of this biotech region - represen- tatives of the universities forming BioRiver Science, the cities, economic promotion agencies and chief administrators, the BioRiver Companies, the Chambers of Industry and Commerce, technology Contact centres and initiatives like Bio-Gen-Tec, bioriver Koordination BioCologne, LifeTec Aachen-Jülich, BioTec Martin Kretschmer Erft and LSA Life Science Agency - they all Phone: (+49) (0) 7 00 - BIORIVER (+49) (0) 7 00 - 24 67 48 37 present the potentials of this leading biotech E-mail: [email protected] cluster worldwide using the brand BioRiver®. Web: www.bioriver.de

39 BioRegion Aachen - Liège - Maastricht

Heartbeat of Life Sciences in Europe In the first stage the project partners focused Meuse Rhine Triangle on common core-competences: for example In the cross-border region, where Germany, biomaterials produced by Matricel located in The Netherlands and Belgium intersect, more Herzogenrath. This young company, located than 200 companies are active in the field of at Herzogenrath technology park, sets Life Sciences. The same region hosts five cartilage-suffered athletes on their feet again Universities, with approximately 17,000 because damaged cartilage doesn’t grow students in medicine, biology, medical together by itself. In future it should be technology or biotechnology and numerous possible to set in patients new cultured research institutes, that set accents in the life cartilage cells on a carrier material by sciences landscape. For that reason the Matricel. Companies like Eurogentec in Liège, European Union supports the programme DSM in Heerlen or DASGIP in Jülich represent „Heartbeat of Life Sciences in Europe -Meuse an additional Life Sciences field in the tri- Rhine Triangle“. In November 2002 the tri- national region: bio-engineering. DASGIP for national region was awarded a contract for instance offers all-round equipment for three years. With an overall budget of A 1.7 fermentation, the production of microbiolo- Million seven partners aim is to create a gically generated materials on a large scale. „Silicon Valley“ of medical technology and Apart from traditional German companies like Grünenthal, Belgian firms like Tibotec work on diagnostics and therapeutics too. The pharmacy company Tibotec from Mechelen develops medication for HIV- treatment meant for people infected with the AIDS-virus. AplaGen from Baesweiler a representative for the field of genomics and proteomics develops a non-hormonal contraceptive pill. Core competence in medical technology: Medtronic, located in the Netherlands, fabricates medical devices for heart-circulation therapy like cardiac pacemakers and cardiac catheters. biotechnology in the cross-border region. The These are many different competences with regional development agency AGIT, located different addresses which should grow at Aachener Technologiezentrum am together. Besides the technology-transfer Europaplatz, is co-ordinating partner of the offices of the Universities of Liège, Maastricht programme. and Aachen the other partners are AGIT, the

40 medical technology centre (MTZ) next to the university clinic of Aachen, Jülich’s High-Tech Mall, the Chemelot High Chem industrial park in Geleen, Sart Tilman Science Park in Liège and in the near future also in the Bio Partner Centre of Maastricht, which is under construction.

Dutch NV Industrial Bank LIOF, the The region is increasingly developing a Municipality of Maastricht and the economic model character for European integration. development agency (WFG) East-Belgium The 3.8 million inhabitants of the tri-national located in Eupen. region enjoy the unique variety of a multi- But there’s more than cumulative Life cultural environment.

Sciences know-how that speaks well for the tri-national region. Via the international airports of Cologne-Bonn, Düsseldorf, Contact Maastricht-Aachen, Brussels and Liège, this Heartbeat of Life Sciences in Europe – region is in reach of major European cities in c/o AGIT Technologiezentrum am Europaplatz just a few hours time. The largest cities in D-52068 Aachen the tri-national region are Aachen with Dr. Ute Schelhaas (project co-ordination) 250,000, Lüttich 200,000 and Maastricht Phone: (+49) (0) 2 41-9 63-10 63 125,000 inhabitants. Life Sciences companies E-mail: [email protected] are able to find an area for research and Ute Steinbusch (public relations) Phone: (+49) (0) 2 41-9 63-10 61 development in several specialised E-mail: [email protected] technology and start-up centres like the Web: www.heartbeatineurope.org

41 Federal state organisation

Hesse

BioRegion Hesse: a Life Science location bridging the entire value chain!

The Federal State of Hesse has always been a traditional location for the chemical and pharmaceutical industries and for medical technology in Germany, with a total of over 100,000 people employed in these areas. Hesse, together with Frankfurt as its economic centre, covers the entire value chain for biotechnology products in diagnostics and therapy, ranging from basic research and clinical research to production, logistics and marketing - the conditions available here are not matched anywhere else in Germany.

Research More than 600 professors and about 17,000 students are engaged in the Life Sciences at five universities, three university clinics and five research facilities. Major focal points include the Centre for Membrane Proteomics and the specialised research work on RNA-ligand interaction in Frankfurt, terrestrial microbiology and tumour research in Marburg, and medical research in Giessen. Other important areas are bionics and metagenomic research in Darmstadt.

Business Hesse is the location of major Life Science companies such as Aventis, Bayer CropScience, Altana, Merck, Fresenius and Merz. These are followed by a dense net of up-and-coming medium-sized firms such as Stada, Biotest or B. Braun Melsungen, to name only a few. And all are flanked by a wide range of service providers in the varied fields of clinical research, production, law, finances, personnel, marketing and sales.

Infrastructure Thanks to its excellent transport structure and its long-established competence in pharmaceutical services, Hesse is an ideal location for maturing biotech companies which have moved out of the research phase and are ready to engage in clinical research, upscaling or production. It has specialised industrial parks

42 where biotech companies will find all the necessary competences enabling them to concentrate on their core business. These include personnel acquisition and training, waste disposal, plant construction and a wide range of highly specialised services. This established competence of Hesse alongside the pharmaceutical value chain is unique throughout Germany and will prove to be of very special advantage for the maturing biotech industry.

Economic Development The Hesse Government specifically promotes Life Sciences and chemistry, and has created a package of programmes for this purpose. The Germany-wide business plan competition Science4Life, implemented in cooperation with Aventis, is aimed at potential founders and offers comprehensive advice and assistance. The Hessen-Invest BioStart grant programme gives entrepreneurs financial support in the pre-seed phase. The entire consulting services about the financial support is localized at one spot: the Beratungszentrum of the InvestitionsBank Hessen AG in Frankfurt. Hesse also possesses a network of incubator centres with specially tailored packages for start-ups. All biotechnology activities of the regional Ministry of the Economy are coordinated by the TechnologieStiftung Hessen.

Contact TechnologieStiftung Hessen GmbH Aktionslinie hessen-biotech Dr. Detlef Terzenbach Abraham-Lincoln-Str. 38-42 65189 Wiesbaden Phone: (+49) (0) 6 11-7 74-6 13 Fax: (+49) (0) 6 11-7 74-6 20 E-mail: [email protected] Web: www.tsh-hessen.de

43 BioRegion

Frankfurt

Biotech goes Business and is ranked within the top 10 research The FrankfurtRheinMain region offers an facilities world wide. The advances made excellent opportunity to capitalise on recent here in Frankfurt in the fields of structural breakthroughs in the life sciences. Its biotech research and bio-informatics put the biotechnology network, business community, Frankfurt business location five years ahead location and infrastructure combine to create of all other German biotech regions, as these the perfect environment for success in the science disciplines form the decisive link European biotech market. As Europe’s largest between innovation and production. „pharmacy“, Frankfurt region hosts more than 100 biotech oriented companies. Many The city of Frankfurt am Main lies at the international companies such as Aventis heart of the European continent. Its strategic location has led Frankfurt to become a centre for trade and commerce. With the largest airport in continental Europe, Europe’s biggest passenger train station, excellent cargo ports (both river and air), access to Germany’s most important Autobahns, unparalleled telecom infrastructure, and continental Europe’s busiest internet hub, the city of Frankfurt is the perfect portal for European market entry. Next to its superb infrastructure the region also has several interesting initiatives for the More than real estate: The advancement of the biotech industry. Frankfurt Innovation Centre

Pharma, Abbott, E. Merck, and Fresenius In the year 2000, companies as well as other provide opportunities for collaborative organizations who are interested in an agreements and strategic alliances. accelerated growth of the biotechnology industry, joined up as the Frankfurt Bio Tech Five universities, 8 technical colleges, and Alliance. This interest group, in which ad hoc over 100 research institutes in the area form working groups formulate biotech projects, the basis for research and development with strives to promote Frankfurt as a biotech a strong focus on structural biotech research cluster on a national and international level and bio-informatics. In these fields, the in order to attract foreign direct investment. University of Frankfurt is endowed with state- The Frankfurt Bio Tech Alliance features of-the-art equipment and research personal Frankfurt biotech firms such as Aventis

44 Roland Koch, Hessian Minister President, and the Mayor of the City of Frankfurt, Petra Roth, at the laying of the cornerstone ceremony of the Frankfurt Innovation Centre

Pharma or Merck KGaA; venture capital firms such as Future Capital AG, as well as Frankfurt’s prominent research and industry park InfraServ Hoechst and the Frankfurt Airport/Tradeport and many other small and medium sized companies.

The new Frankfurt Innovation Centre for Biotechnology (FIZ) links the financial, pharmaceutical, and biotechnology sectors and moves ideas and projects from mind to market. The FIZ is more than just a real estate project. Its management takes the leading role for the development of the life science industry in Frankfurt by Contact implementing and accelerating new Frankfurt Bio Tech Alliance processes which are not being sufficiently Dr. Thorsten Strube Altenhöferallee 3 driven by the market economy. 60438 Frankfurt

Phone: (+49) (0) 160-91 34 08 29 Fax: (+49) (0) 60-2 19 71-6 13 E-mail: [email protected] Web: www.biotec-frm.de

45 BioRegion

Marburg

Future technologies in Marburg: regard. The vision that the success story of Biotechnology Initiative noble-prize winner and entrepreneur Emil Marburg von Behring could be repeated is shared by One of Marburg’s most many professionals active in the promotion outstanding economic of economic development. Therefore, a close- development factors surely is meshed promotion network for company the field of life sciences as do founders and young companies has been show not only the rates of established. growth of the companies that have developed from the Especially for life sciences the conditions in former Behringwerke. Also the Marburg are most favourable, since the Philipps-University departments of biology, combination of university, Max-Planck- chemistry, medicine and pharmacy together Institute, the Behring successor companies with the Max-Planck-Institute are an and municipal administration offer location impressive demonstration of the scientific factors unique as to their regional density and economic potentials available in that and concentration. The Philipps-University region. Top field positions in inter-university assists in the so-called ‘gentle foundation ranking and the many company conceptions scheme’, by supplying laboratory equipment from Marburg that were prize-winning in the for a limited period of time. The town itself nation-wide Science4Life contest convincingly offers low-price laboratory premises in the underline Marburg’s reputation in this newly-created Natural Sciences Foundation

46 Centre, the Naturwissenschaftliches Offers a virtual direct link to network Gründerzentrum (NTZ). In already well- partners on Federal Government and federal established large and small BioTech- state levels is installed. Substantial is also the companies (e. g. Aventis Behring, Dade survey over the industrial site areas available Behring, Chiron Behring, Mochem, Taros together with the respective responsible to Custom, and Vectron Therapeutics) young address. News informs on latest news, founders find potential partners providing occurrences and events. To further improve expert knowledge. the conditions for biotechnology in Marburg, To promote the development and practical public forums together with the university use of biotechnology in Marburg the town and other promotional institutions are started a Biotechnology Initiative together planned for the future, as well as sporadic with representatives of the federal state of BioTech meetings presenting research Hesse, the university, the Max-Planck-Institute priorities and main fields of activity and the and the Behring successor companies. opportunity to talk and exchange ideas with Potential founders and young start-up experts. These meetings shall take place companies receive practical assistance by about four times a year and become an procuring co-operation partners and showing ‘institution’ in Marburg

and offering them possible sponsoring sources. This Biotechnology Initiative has an advisory board consisting of key executives of the university, the Max-Planck-Institute, the Behring successor companies, the federal state of Hesse, and the town of Marburg.

In its latest internet presentation the Contact Initiative shows all at one click under Biotechnologie Initiative Marburg www.initiative-biotechnologie.de. Relevant Phone: (+49) (0) 64 21-2 01-5 58 research priorities and their representatives Fax: (+49) (0) 64 21-2 01-2 93 are as well presented as the methods and Dr. Jochen Stauder equipment of university institutions and the E-mail: [email protected] Dr. Roloff Johannsen product lines of Marburg’s BioTech E-mail: [email protected] companies. At Förderangebote / Promotion Web: www.initiative-biotechnologie.de

47 Federal state organisation Baden- Württemberg

Biotechnology and Life Sciences in Baden-Wuerttemberg Promotion and strengthening of scientific and economic opportunity

Biotechnology and life sciences are developing into an innovation engine for the new century. With the establishment of the state foundation BIOPRO Baden-Württemberg GmbH, Baden- Wuerttemberg has created an instrument for mobilising the strengths of the leading biotech location on both a national and international level for today and for the future.

Biotechnology is one of the most important growth markets and will, being a typical cross- sectional technology, have a substantial influence on the development of many scientific and economic areas. These include human and veterinary medicine, the industrial chemical production including pharmaceutical production, agriculture and nutrition as well as environmental protection. In Baden-Wuerttemberg, biotechnology is currently going through a consolidation process. However, the future prospects for the region are excellent because of the overall economic and scientific environment. To develop these general conditions further in the short term, BIOPRO Baden-Württemberg GmbH was founded at the beginning of 2003 as a strategic partner for international location marketing and the industry-specific promotion of trade and industry. Under the leadership of Dr. Ralf Kindervater, BIOPRO Baden-Württemberg GmbH focuses, apart from the above-mentioned measures, on the industry-specific presentation of the competences in science and research of the universities, advanced technical colleges, and private research institutions as well as the strengthening of technology transfer.

The excellent and highly diverse research landscape in the area of life sciences in Baden- Wuerttemberg is complemented by a large number of biotechnology companies. There are approximately 140 young research-intensive biotech companies in the South West - of these 67 are core biotechnological industries - developing and utilizing methods and processes of modern biotechnology. Numerous companies work in the broader areas of the life sciences: These include approximately 210 companies from the area of medical technology, including 170 companies focusing on laboratory equipment and 40 consulting companies, supplemented by 114 small and medium-sized as well as eight large pharmaceutical companies. The number of genetic engineering facilities has exceeded 1000. In particular, in the area of pharmaceutical industries, the growth potentials have become apparent. At the end of this decade, approximately 40% of the profit will come from biotechnology. It is the task of several transfer agencies to join science with industry. Coordination offices, such as the Technology Licence Office (TLB), the Steinbeis Transfer Centres, ifex, and the Agency for International Economic Cooperation (GWZ) are responsible for - in cooperation with the BIOPRO Baden-Württemberg GmbH - services such as marketing and

48 administration, and the provision of advice regarding patenting and strategy matters. The targeted development of the Baden-Wuerttemberg area is excellently mirrored in the establishment of biotechnology parks in the four BioRegions of the area: Rhine-Neckar-Triangle, Stuttgart/Tübingen/Esslingen/Reutlingen (STERN), Freiburg, and Ulm.

The concept of success of the biotechnology location Baden-Wuerttemberg is based on the extraordinary high concentration of highly efficient research institutions. Life science research is carried out at eight universities and the four associated university hospitals. Internationally- renowned research institutions such as the European Molecular Biology Laboratory (EMBL), the German Cancer Research Centre (DKFZ), and five Max Planck Institutes focusing on life science research complement this spectrum. The major focus of the research undertaken in these institutions lies on the neurosciences, molecular and cellular biology, plant sciences, genomics, developmental biology, tissue engineering, microbiology/infectiology, bioengineering, biocomputing/systems biology, microarray technology, nano-biotechnology, and structural biology. In the biotechnological sector, the research landscape of Baden-Wuerttemberg is among the most efficient and most diverse.

Biotechnology and life sciences are also supported by the Science Minister and the Minister of Trade of the State of Baden-Wuerttemberg procuring numerous measures such as funding programmes and trade fairs. In February 2001, the renowned molecular biologist Professor Konrad Beyreuther was appointed State Councillor for the Protection of Life and Health of the State of Baden-Wuerttemberg. The establishment of three life science centres received approximately A 60 million: These include the Centre for Biosystems Analysis, the Centre for the Quantitative Analysis of Molecular and Cellular Biosystems - Bioquant, and the ZytoOrganoPoese Research Network. The

„Biotechnology Offensive“ of the state of Baden- Contact A Wuerttemberg is supported with 29 million. In 2002, BIOPRO Baden-Württemberg GmbH Baden-Wuerttemberg initiated the GeneStart biotech Dr. Ralf Kindervater award, an international business plan competition in the Breitscheidstraße 4 70174 Stuttgart area of biotechnology. Phone: (+49) (0) 7 11-90 71 52 00 Fax: (+49) (0) 7 11-90 71 52 02 E-mail: [email protected] Web: www.bio-pro.de

49 BioRegion Rhine- Neckar Triangle

The BioRegion Rhine-Neckar Triangle is one and molecular medicine, particularly in the of the leading biotechnology locations in fields of cancer research, immunology and Europe: The European Molecular Biology virology. These areas are supplemented by Laboratory, the German Cancer Research competence in cell culture and screening Centre, the Centre of Molecular Biology of technologies at Mannheim University of Heidelberg University, the Max-Planck- Applied Technology and Design, in Institute for Medical Research, the institutes bioinformatics and applied mathematics by and university hospitals of Heidelberg and the University of Mannheim, in microbiology Mannheim, the Mannheim University of and mycology at the University of Applied Science and the University of Kaiserslautern and plant gene technology at Kaiserslautern, all contribute to the excellent the Centre for Green Gene Technology in science base in molecular biology and Neustadt/Weinstrasse. Altogether, about molecular medicine. 3,200 scientists in research institutions are working in biotechnology-related areas. Research focuses on functional genomics and proteomics, bioinformatics, neurobiology, The region also comprises international chemical/pharmaceutical companies such as BASF and Abbott in Ludwigshafen, Roche Diagnostics in Mannheim and Merck in Darmstadt with proprietary R&D departments in biotechnology.

Since the BioRegio Competition of the federal government in 1996, when the

The Heidelberg Technology Park provides 50,000 m2 for labs and offices - the largest facility of its kind designed for biotechnology and life sciences

50 BioRegion Rhein-Neckar-Dreieck was awarded the infrastructure within which as a „Model Region“, the number of small biotechnology can develop into a thrieving and medium-sized enterprises in biotechno- sector as well as ensuring adequate training logy in the BioRegion Rhine-Neckar Triangle facilities for skilled workers to achieve a has risen from 31 to more than 85, providing critical mass in the region’s biotech industry. highly qualified jobs for 1,800 people. Almost In doing so, the BioRegion Rhein-Neckar- 80 per cent of this workforce is employed by Dreieck will be established as one of the about 45 companies engaged in research and most significant biotechnological areas in development, particularly in the drug Europe with a potential to compete discovery process. The innovative strength of successfully with the strong biotech clusters the biotech companies, together with the in the US. know-how and capacities of the big pharma- ceuticals companies and the scientific Biotech companies in Rhine Neckar Triangle 90 excellence of the academic institutions 80 70 provide a competence network in which 60 50 number of 40 biotech SMEs biotechnology can flourish. Technology Parks 30 20 10 in the cities of Heidelberg, Mannheim and 0 1996 1997 1998 1999 2000 2001 2002 Ludwigshafen provide lab and office space as 1800 well as professional advice for setting up and 1600 1400 financing business. 1200 1000 800 jobs in 600 bioch SMEs Research institutions and industry, in 400 200

0 conjunction with local authorities, chambers 1996 1997 1998 1999 2000 2001 2002 Status: 31.10.2002/EJ of commerce, financial institutions and companies in the services sector, have Contact formed BioRegion Rhein-Neckar-Dreieck e.V., BioRegion Rhein-Neckar-Dreieck e.V. a registered society that serves as an efficient Dr. Ernst-Dieter Jarasch Im Neuenheimer Feld 582 decision-making body. The society’s main 69120 Heidelberg objective is to initiate development programmes in close co-operation with Phone: (+49) (0) 62 21-6 49 22-0 Fax: (+49) (0) 62 21-6 49 22-15 federal and state authorities and the capital E-mail: [email protected] market. Furthermore, its goal is, improving Web: www.bioregion-rnd.de

51 BioRegion Stuttgart Tübingen Esslingen Reutlingen Neckar-Alb

One-Stop-Shop for Biotechnology in the STERN Region The establishment of BioRegio STERN Management GmbH goes back to the participation in the BioProfile competition © Lichtenscheidt/Max-Planck-Institut held by the BMBF (Federal Ministry of für Entwicklungsbiologie, Tübingen Education and Research) in 2001. As one of the winners, STERN BioRegion will receive investment funding of more than A 15 million for young enterprises focussing on the promising field of regeneration biology over the next five years.

The major focus of the company is to promote a wider recognition of the „STERN“ region as a centre of excellence for biotechnology within the state of Baden- Wuerttemberg itself, in the whole of Germany and in all other parts of the world. STERN stands for Stuttgart, Tübingen, Esslingen, Reutlingen and the Neckar-Alb area which form a network to promote biotechnology in the region and to attract firms and venture capital to S.W. Germany. The partners of STERN BioRegion attach great importance to economic potential in

© Lichtenscheidt/Max-Planck-Institut für the field of biotechnology. Thus it is not Entwicklungsbiologie, Tübingen surprising that the Stuttgart Region won the

52 © Technologiepark Tübingen-Reutlingen GmbH

„Award of Excellence for Innovative Regions“ institutions which already exist there. STERN from the European Commission for two also organizes publicity and marketing consecutive years as the most innovative area events, coordinates BioRegio activities and in Europe. takes part in international tradeshows and

The „BioRegio STERN Management GmbH“ has set itself the demanding goal of making Contact the STERN BioRegion one of Germany’s BioRegio STERN Management GmbH leading biotechnology locations. To reach Dr. Klaus Eichenberg Friedrichstraße 10 this goal, the company functions as a central D-70174 Stuttgart contact point or one-stop-shop advising the region’s biotechnology companies, young Phone: (+49) (0) 7 11-87 03 54-0 Fax: (+49) (0) 7 11-87 03 54-44 entrepreneurs hoping to set up in the region E-mail: [email protected] and the numerous renowned research Web: www.bioregio-stern.de

53 BioRegion

Ulm

The BioRegioUlm is the central location for forms an attractive cooperation model in biotechnological manufacturing in Europe - immediate proximity. especially for the biotechnological production - The University of Applied Sciences in of drugs. Companies of the region feature Biberach starts a new study programme in through almost thirty years of experience in pharmaceutical biotechnology. biotech-manufacturing. - Significant accession of employments, e.g. Boehringer Ingelheim Pharma KG adds 400 Potentials of BioRegioUlm new jobs in the biopharmaceutical - The largest number and amount of production department; The companies genetically engineered drugs in Europe are Vetter and Rentschler have engaged 450 produced in Bioregio Ulm. resp. 80 new employees; - A considerable amount of facilities in - Large investments were made by these genetic engineering in Baden-Wuerttemberg companies (Boehringer Ingelheim im are located in the region between Aalen and Biberach A 300 million, Rentschler about Konstanz. A 20 million, Vetter more than A 17 million).

- The Science City of Ulm with the University The Companies of Ulm, the University of Applied Sciences, Boehringer Ingelheim Pharma KG has Public and Industrial Research Institutes doubled its capacity for biopharmaceutical

54 performance optics and medical apparatus), Grünau Illertissen (food technologies), Paul Hartmann (health care products). Through the development of these companies and the foundation of 30 new start- ups with about 150 jobs the number of the biotech- employments has risen to more than 2,200 during the last years. The Association for the production in Biberach. Already the Advancement of Biotechnology in the „Biotechnicum“ was the leading genetic BioRegioUlm is the platform for the further engineering facility in Europe for drugs development of biotechnology in the region. isolated from cell culture. Rentschler The main focus of the activities are the Biotechnology offers the production and promotion of the cooperation in the region, accreditation of recombinant proteins for consultation in questions of setting up therapeutical applications - from the gene to business, the encouragement of young the development of the process of scientists as well as public relation and manufacturing in laboratory or commercial information. scale. Vetter handles biotechnologically produced substances with high level technology and ist specialized in the field of aseptically filled application systems. Labor Contact Dr. Merk und Kollegen synthesizes virus- and BioRegioUlm Förderverein Biotechnologie e.V. bacterial antigenes as well as recombinant Dr. Gabriele Gröger Albert-Einstein-Allee 5 proteins in industrial scale. The profile of the D-89081 Ulm BioRegioUlm is further characterized by companies like Merckle/ratiopharm (one of Phone: (+49) (0) 7 31-5 02 20-04 Fax: (+49) (0) 7 31-5 02 20-16 the most successful German producers for E-mail: [email protected] pharmaceuticals), Carl Zeiss (high Web: www.bioregioulm.de

55 BioRegion

Freiburg

BioRegion Freiburg - a successful region including the Fraunhofer Institute of Physical within the BioValley Measurement Techniques, which is active in The BioRegion Freiburg is located at the the field of bioanalytics. point where Germany, France and „Centres of Excellence“ have sprung up in Switzerland all meet. It is a partner in the tri- the areas of oncology, immunology, tissue national BioValley network, which pools the engineering, plant biotechnology, biotechnology potential of the centres of nanotechnology and neuroscience. Freiburg (D), Basle (CH) and Strasbourg (F). Particular mention should be made of the With more than 400 biotech-companies, high-performance technology transfer from including global players like Novartis, Aventis the University of Freiburg, whose portfolio and Roche, and more than 200 research takes in all the eminent high-tech companies. institutions, BioValley is able to offer outstanding competence. Four universities With more than 100 biotech companies, and the tri-national including 40 which are R&D companies, and university course in more than 45 start-ups since 1996, the biotechnology BioRegion Freiburg is one of the most produce highly- successful German biotech regions. qualified employees. BioValley is one of The Technology Europe’s most attractive Foundation biotech-clusters. BioMed Freiburg was set The BioRegion Freiburg is up in 1996 as a known for its excellent and central network for the region by highly diverse research and political, research and economic company landscape. interests with the aim of creating This takes in the secure jobs. As the central coordination point University of Freiburg, for the BioRegion Freiburg, it additionally with its unique Faculty of provides a broad range of consultancy Applied Science, one of the biggest university services relating to concept work, financing hospitals, the Max Planck Institute for and dealing with the authorities. The Immunobiology, the Tumor Biology Centre regional private equity company of the as well as five Fraunhofer Institutes, Sparkasse Freiburg-Nördlicher Breisgau is

56 also highly committed to the field of biotechnology. At the same time, the Foundation runs the BioTechPark Freiburg, which offers optimum start-up and working conditions for both young and established biotechnology companies. A total of 6,000 m2 individually- configured laboratory and office space is available to start-ups, which are promoted with a low-cost, graduated rent over a period of seven years, and a further 24,000 m2 are available in the InnovationCentre Freiburg. The fully-equipped start-up laboratory offers creative scientists the chance to put their ideas into practice without any investment expenditure. Companies are integrated in the BioRegion Freiburg network right from the start and have the opportunity to remain in the same premises and undergo expansion there after their seven-year assisted period has come to an end.

BioDigital, the international trade fair and conference on IT and Instrumentation for Pharmaceutical and Systems Biology Research, is held every two years in Freiburg, offering a Contact platform for communication and discussion. BioRegio Freiburg We have been fortunate in being able to Dr. Bernd Dallmann / Dr. Thea Siegenführ Rotteckring 14 attract the eminent event organiser „IBC Life 79098 Freiburg Sciences“ to run the associated conference. Phone: (+49) (0) 7 61-38 81-8 26 Fax: (+49) (0) 7 61-20 20-4 74 E-mail: [email protected] Web: www.bioregion-freiburg.de

57 Federal state organisation

Bavaria

Network ‘Life Science Bavaria’ Bavaria is one of Europe’s leading Biotech Regions. Along with Munich (Martinsried and Freising- Weihenstephan), Regensburg, Würzburg, Erlangen and Bayreuth provide excellent sites for the scientific and industrial development of biotechnology. This infrastructure is complemented by the presence of large chemical and pharmaceutical industries and international companies in the food as well as the medical engineering sector that use biotechnological processes in a wide range of applications.

The dynamics and pace of development in biotechnology research along with the broad range of its potential applications mean that national and international networking between partners is essential.

58 With this in mind, Bayern Innovativ GmbH established the Network ‚Life Science Bavaria’ together with the coordinators of the Bavarian Bioregions - BioM AG, BioPark Regensburg GmbH and BioMedTec Franken e.V. - and with the support of the Bavarian State Ministry for Economic Affairs, Infrastructure, Transport and Technology.

The goal of the Network is to provide up-to-date information about the latest developments and emerging trends in biotech, as well as to initiate personal contacts so that novel constellations of national and international cooperation can be realised. New themes and their implementation will bring potential partners on an interdisciplinary level together.

The Network ‚Life Science Bavaria’ encompasses subjects around biotechnology that range from drug development, plant genetics in agriculture, functional food in nutrition, biotooling and tissue engineering for medicine or bioprocess engineering in the chemical industry and the environmental area.

A portfolio of platforms ensures that the Network ‘Life Science Bavaria’ can stimulate cooperations along the value chain and across disciplines. These platforms include congresses such as the ‘Forum Life Science’, cooperation fora, one-on-one cooperation meetings, joint stands at international high-tech fairs as well as individual technology transfer projects. The quarterly Newsletter brings the latest Biotech news from Bavaria, while the homepage www.lifescience- bavaria.de goes further, offering competence profiles and cooperation interests from companies and institutes as well as daily updated news.

Information: www.lifescience-bavaria.de

Contact Bayern Innovativ GmbH Netzwerk „Life Science Bavaria“ Dr. Matthias Konrad / Dr. Kerry Tzu-Hui Nip Gewerbemuseumsplatz 2 D-90403 Nürnberg

Phone: (+49) (0) 9 11-2 06 71-0 Fax: (+49) (0) 9 11-2 06 71-7 66 E-mail: [email protected] Web: www.bayern-innovativ.de www.lifescience-bavaria.de

59 BioRegion

Franconia

The BioMedTec Franken-Triangle: institutions form a stronghold for the Joining forces between the university development of new pharmaceuticals. cities of Würzburg, Erlangen-Nuremberg and Bayreuth Erlangen-Nuremberg - Medical Technology: The specialized life science profiles of each of The city of Erlangen and the University of the universities within the BioMedTec Erlangen-Nuremberg strive to become Franken-triangle contribute to a Germany’s federal capital of medical complementary and comprehensive research, production and services. Some spectrum of research and technologies - the recent highlights include the new Institute of basis for new commercial applications. Medical Technology and chairs in Bioengineering and Structural Biology. The new graduate programme „Medical Technology“ stresses the particular emphasis on this research area. The graduate programme „Molecular Medicine“ has become a benchmark for similar programmes elsewhere.

Würzburg - Biomedicine: Würzburg completes the triangle. In biomedicine, Würzburg attracts the second highest federal grants of all German

Biomed/ZmK

Bayreuth - Structural Biology and Biochemistry: Bayreuth has the smallest university of the triangle, collecting, however, the largest amount of federal research grants (DFG) per scientist in the field of biomedicine in Germany. Bayreuth contributes renowned structural biology, featuring a top modern NMR Centre. A new interdisciplinary incubator for applied biomedical research projects will be finished in 2004. Those RSG Bad Kissingen

60 universities. The Theodor-Boveri Institute for same building complex as the new Institute Biosciences and the newly awarded Rudolf- for Medical Technology and is situated Virchow-Centre for Experimental within walking distance to many university Biomedicine are but two prestigious institutes and to Siemens Medical Solutions. institutions that keep up this tradition of world class interdisciplinary research. Companies: Franconia is the youngest of the Würzburg has installed the first Institute for Biotechnology regions in Bavaria, but Bioinformatics in Northern Bavaria, an growing quickly. Out of almost 40 important building block in the Franconian companies, 19 have been founded since Bioinformatics Network. 2000, mostly spin-offs from the universities. Many of them develop pharmaceuticals in BioMedTec Franken e.V.- Network oncology, heart, neurodegenerative and Management: infectious diseases on the basis of proprietory BioMedTec Franken e.V. was founded by technologies. scientists from the three Franconian universities as a non-profit organisation in 1999. Its purpose is to build a biotechnology- community in Franconia, to support biotechnology start-ups with information and network-contacts, to initiate and coordinate new collaborative projects and to attract public funding and investors to Franconia. The network is supported by the „Bavarian High Tech Initiative“. It comprises the universities, companies, administration, and other support organisations. BioMedTec Franken is part of the Network Life Science Bavaria. IZMP Incubators: Besides the established incubator RSG in Bad Kissingen, brand new facilities for start-up companies are available in Franconia. Since Contact 2001 the „BioMed/ZmK“ in Würzburg BioMedTec Franken e.V. provides laboratory and office space for Dr. Stephan Schröder-Köhne biomedical and information-technology Managing Director companies. The surrounding Science Park Friedrich-Bergius-Ring 15 D-97076 Würzburg has ample space for expansion and new Germany settlement. The technology-centre „Medical Technology and Pharma“ in Erlangen has Phone: (+49) (0) 9 31-2 99 88-75 Fax: (+49) (0) 9 31-2 99 88-94 started operation in 2003. The IZMP comes E-mail: [email protected] with built-in synergies as it is located in the Web: www.biomedtec-franken.de

61 BioRegion

Regensburg

several assistance measures on the part of the Federal Ministry of Education and Research (bmb+f) may be mentioned here. Also the services of well-known foundations such as José Carreras or Volkswagen have been obtained for the research work. Research is being done in Regensburg on therapies to combat cancers such as leukaemia and brain tumours as well as on the development of serums to fight AIDS. Furthermore the Regensburg research groups are involved in the fight against Alzheimer’s Building of the BioPark Regensburg GmbH and Parkinson’s Diseases, too. In the field of infection biology the medical centre is a B i o R e g i o R e g e n s b u r g - partner of the renowned World Health Successes „Made in Regensburg“ Organisation (WHO). Regensburg is also the focus of new technologies and is developing The BioPark Regensburg GmbH is the competence centres for telemedicine and management and coordination centre of the sensor technology. biotechnology cluster BioRegio Regensburg in the heart of Europe. Currently 34 companies with 1000 employees are active in the biotechnology cluster, the so-called BioRegio Regensburg. They recently achieved sales totalling some A 100 Million. The BioRegio Regensburg has thus developed into the second most important biotechnology region in Bavaria after Munich.

With its University, University of Applied Sciences and the medical centre, Regensburg possesses the best state-of-the-art facilities in Opening ceremony with Dr. Edmund Stoiber, Bavarian Minister President, Hans Schaidinger, Bavaria. Various special fields of research of Mayor of the City of Regensburg and Dr. Thomas the German Research Association (DFG) and Diefenthal, CEO of BioPark Regensburg GmbH

62 With the foundation of BioPark Regensburg Incorporation(C-TRI) from South Korea, GmbH in 1999 the successful efforts of the combines its European research activities federal BioRegio Initiative (1996) and the with those of the University of Regensburg at regional High-Tech-Offensive of the State of BioPark Regensburg together with KoBioVen Bavaria (1999) focused in a biotechnology (Korean Bio Venture Association), which runs centre with top-quality laboratory space of its European office from here and therefore 6,000 sqm on the university campus. underlines the strategic alliances of the City Through the integration of the BioPark into to Seoul. The Cluster of BioRegio Regensburg the regional Northern Bavaria Business Plan also includes well-known companies like Competition the young entrepreneurs were Wilden AG, Bionorica AG or Baxter AG. Due able to make themselves better known and to continual growth, BioPark II (2005, to regularly hold their own among the top ten. double space) and the development of a For example, for three Regensburg Technology Park Regensburg (2007) are in companies prizes were awarded at the the planning stage. BioChance Competition sponsored by the Federal Ministry of Education and Research. A competence centre for Fluorescent Bioanalysis of the University of Regensburg was established in 2002 into the now booked out BioPark building as interface between universities and economy in the region.

The integration of established firms, with their experience and know-how, was also very successful in Regensburg. Companies like Antisense Pharma GmbH with 30 employees is one of the biggest at BioPark and is conducting clinical tests in Regensburg. And it is in the pharmaceutical and biotechnology field that everything revolves around Companies and institutions in BioPark global markets. In consequence the Regensburg and the Regensburg area establishment of international companies Contact and institutes is also of special significance. BioPark Regensburg GmbH Dr. Thomas Diefenthal, Ph.D. The US-NASDAQ-listed biotech company Josef-Engert-Str. 9 D-93053 Regensburg Tularik Inc. in San Francisco conducts its Germany European business and research activities since 2000 at the BioPark Regensburg and is Phone: +49 941-920 460 Fax: +49 941-920 4624 owned in 2004 by Amgen Inc. E-mail : [email protected] Another firm, ChemTech Research Web: www.bioregio-regensburg.de

63 BioRegion

Munich

Close links between science and industry Two universities, two polytechnic institutes, three biology-oriented Max Planck Institutes, the Research Centre for the Environment and Health (GSF) as well as several service companies make Munich to what can be described as a cluster. An important factor for success of the BioTech-Region München is the close proximity of excellent scientific institutes and universities, a large number of The gateway to the Munich biotech region: successful financing rounds and deals, The Innovation and Foundation Centre for Biotechnology (IZB) in Martinsried consequent support of biotechnology on the part of the Bavarian Regional Government, excellent infrastructure and, above all, a critical mass of excellently qualified personnel.

Pacemaker of the region - BioM BioM is a financing, service and consulting Leading Position in Germany company whose aim is to promote the After an explosion in the number newly- development of the BioTech-Region München founded companies in the 1990s, there are now over 150 life science firms in the Greater Munich Area, among these are 100 small and medium sized biotechnology firms. The workforce in the BioTech-Region München has increased tenfold in as many years and now reaches over 2500 employees. Munich is the leading biotech region within Germany with respect to the number of products in the clinical phase: over 70 products are Full pipeline: Compared to other German regions companies in the Munich area have currently in the pipeline, many being in, or the largest number of product candidates in related to, the field of oncology. clinical phase I-III

64 The new biotech centre in the North of Munich: Fighting cancer: Many companies in Munich The IZB in Weihenstephan focus on new oncological therapies as an internationally renowned centre of biotech company. The young firms are also excellence in the field of innovative offered the possibility of participating in biotechnology. It is the first point of contact larger exhibitions, partnering conferences for biotech start-up companies seeking and other events. financial support or business advice. Through the BioM network which includes all BioM has set up a seed-finance programme to important players in the region (represen- provide young and promising biotechnology tatives from public offices, scientific companies with venture capital in the initial institutions, venture capitalists and biotech seed- and start-up phases. Since the companies), BioM assists Munich-based beginning of 2002, BioM also manages a companies in finding the right contacts and Venture Capital Fund for later-stage partners. Part of an additional service offered investments primarily in unquoted growth by BioM is the organization of seminars and companies and start-ups in the field of Life workshops on a broad range of topics Sciences. relevant to the successful development of a

Contact BioM AG Prof. Dr. Horst Domdey Am Klopferspitz 19 82152 Martinsried

Phone: (+49) (0) 89-89 96 79–0 Fax: (+49) (0) 89-89 96 79–79 E-mail: [email protected] The BioM team Web: www.bio-m.de

65 Biotech success stories

Axxima Munich Axxima® Pharmaceuticals AG is a research- The company is managed by Dr. Yoram based drug discovery company focusing on Karmon (CEO), Dr. Gerhard Müller (CSO) and kinases as drug targets. The company has Clive Krückemeyer (CFO). The company was built a wide range of unique and powerful founded by a group of experienced scientists platform technologies, tailor-made for the led by Dr. Axel Ullrich, Director of the protein kinase target family that reflects the Molecular Biology department at the Max- role of Axxima as a kinase powerhouse. Planck-Institute for Biochemistry in Martinsried and is operating since 1998. In Axxima has successfully pioneered the novel August 1999, Axxima set up its subsidiary, strategy of generating a „Signal Transduction Vichem Kft, in Budapest, Hungary. Axxima’s Firewall“ against infectious diseases by headquarters are in Munich since March blocking critical signaling pathways and 2003. developed several novel kinase inhibitor classes that address novel mechanisms of In three private financing rounds Axxima has action. Axxima’s kinase inhibitors also possess received a total of A 54 million from German a significant upside in other indication areas, and international investors. Lead investor of such as cancer, inflammation and disorders of the third financing round was Bear Stearns the metabolic, immunological and Health Innoventures, New York. The previous neurological systems. financing rounds were led by Techno Venture Management of Munich, Germany. Currently Axxima’s approach to drug development is the Company’s staff totals 65, located at based on the use of its proprietary pre- Axxima’s headquarters in Munich, Germany, optimized drug-like lead compounds. These and at its Hungarian subsidiary Vichem Kft. „Masterkey“ chemical entities offer the in Budapest. opportunity to start novel kinase inhibitor projects with an almost fully optimized compound. Axxima can select the disease field of application based on medical need, commercial and marketing criteria and develop novel 2nd generation kinase inhibitors with improved selectivity profiles and superior safety properties.

Tapping its pipeline, Axxima plans to out- license, sell or partner products at defined development stages to customers in the pharmaceutical industry. www.axxima.de

66 Biofrontera Leverkusen Biofrontera AG, a privately-held biotech company, was founded in 1997 and is located in Leverkusen, Germany. Biofrontera has a unique natural compound collection and strength in natural compound Biofrontera has built a well-balanced project modification, which it combines with pipeline with a first project in Phase II proprietary molecular and in vivo clinical trials, followed by research projects at pharmacology, to build a pipeline of novel various stages of preclinical development, neuroinflammatory drugs. lead finding and optimization. Interim results of the Phase II study of Biofrontera’s lead Biofrontera AG holds two wholly-owned candidate demonstrated excellent efficacy. subsidiaries, Biofrontera Discovery GmbH in Heidelberg and Biofrontera Pharmaceuticals Technology modules available for contract GmbH in Leverkusen. research are listed below: - natural compound libraries Biofrontera Discovery concentrates on lead - screening services on natural compounds discovery and optimization, based on unique - lead optimization services collection of more than 50,000 fungi, soil and - pharmacology services (in vitro, in vivo marine microorganisms. compound profiling) More than 2 mln. natural compounds in - contract research on selected indications prepurified fractions are available for screening. The technology platform comprises high throughput screening, fermentation, and synthetic chemistry.

Biofrontera Pharmaceuticals’ focus is to build a drug pipeline of neuroinflammatory drugs, using molecular, cellular and in vivo pharmacology, with a strong emphasis of integrating genomics technologies. The technology platform allows drug profiling based on neuroanatomical, biochemical and behaviour tests combined with highly sensitive transcriptome analysis on selected animal models for neurodegenerative disorders. www.biofrontera.de

67 Biotech success stories

Brain Zwingenberg BRAIN AG focuses on the discovery and screening and to validate potential candidates development of novel bioactives, enzymes and with modular signal transduction drugs. In a unique approach to the components. identification and production of new natural These validated resources, combined with compounds and biocatalysts the company scientific expertise and technical skills enable applies advanced molecular biology the company to rapidly identify novel technologies to benefit from so far untapped biomolecules to meet the demands for biodiversity. Its success is centred around the enzymes, biocatalysts, cosmeceuticals, powerful EvoSolution® discovery platform nutriceuticals and new pharmaceuticals in with a proprietary BioArchive comprising the bioprocessing and chemical as well as in millions of genes of as yet uncultivable micro- the pharma and life science industries. organisms and of microbial isolates. BRAIN’s team of 40 scientists, graduate The „metagenome“ libraries contain cloned engineers and technicians handles fully DNA fragments representing the genomes of integrated projects within the framework of habitat-specific communities of micro- contract research agreements, R&D organisms, more than 99 percent of which partnerships and alliances with industrial are generally uncultivable. They encode a partners as well as universities and institutes. wealth of novel enzymes and entire metabolic Through in-house projects the company pathways. BRAIN creates Large-Insert-Libraries constantly validates and builds up its (LIL“) and Activity-Based-Expression-Libraries resources and keeps abreast of latest (ABEL“) out of these libraries to exploit this technological advances in molecular and cell biodiversity. BRAIN also offers a tool-box for biology. With its state-of-the-art research functional cell-based assays to identify leads facilities, know-how and commitment to from natural compound libraries in a primary custom-made, cost-effective and confidential collaborations BRAIN has established itself as a reliable and competent partner. BRAIN was founded in 1993 as a privately owned and independent research corporation by Dr. Holger Zinke (CEO) and Dr. Jürgen Eck (CSO). BRAIN resides in a Bauhaus-style industrial building which was acquired in 1996 and entirely restored to a fully integrated infrastructure.

www.brain-biotech.de

68 Cellzome Heidelberg Cellzome is a drug discovery company potential partners. To date Cellzome has building a R & D pipeline in chronic diseases, entered research collaborations with Johnson with a primary focus on Alzheimer’s disease. & Johnson Pharmaceuticals R & D and Bayer Cellzome is leveraging its powerful drug HealthCare AG. proteomics engine to generate an ongoing pipeline, both for in-house drug development Cellzome is seeking strategic drug discovery and through partnership. Founded in a collaborations in Alzheimer’s disease. In partnership with the European Molecular addition, the company is partnering its Biology Laboratories (EMBL), Cellzome has powerful drug proteomics engine for drug combined scientific leadership with discovery. experienced pharmaceutical industry management.

Cellzome’s unique drug proteomics platform, a combination of chemical proteomics and pathway expansion, enables de-risked lead optimization and generates a strong pipeline of efficient drug candidates for chronic human diseases. With its chemical proteomics capabilities, Cellzome takes existing drugs and pharmaco- logically active compounds to identify their protein targets in the human proteome. These protein targets are then mapped on cellular Cellzome is a privately held company. In pathways using Cellzome’s pathway expansion March 2003 the company completed its Series technology, detecting the link between the C funding at an amount of approx. A 30 drug, its protein target and the disease million. Cellzome’s investors include Advent pathway. The technology platform allows International, Atlas Venture, Biofrontier efficient and scalable chemical proteomics Partners, Heidelberg Innovation, Index and pathway expansion experiments to be Ventures, Invesco Private Capital, Schroder performed in a broad variety of cell types and Ventures Life Sciences, SG Asset Management, tissues. This process generates a strong Sofinnova Partners, and Yamanouchi Venture pipeline of opportunities both for Cellzome’s Capital. in-house drug discovery as well as for partnerships.

Cellzome is in active discussions with leading pharmaceutical companies and other www.cellzome.com

69 Biotech success stories

DeveloGen Göttingen DeveloGen is a biology driven drug discovery President of the Federal Republic of Germany company developing innovative therapies for in 1999. In further studies DeveloGen scientists type 1 and type 2 diabetes, obesity and showed that the developmental control gene metabolic syndrome. Founded as a spin-off of Pax4 is able to drive the differentiation of the Max-Planck Institute for Biophysical progenitor, or stem cells, into insulin Chemistry, DeveloGen started operations in producing cells, both in-vitro and in-vivo. After 1998 and currently has close to 80 employees. transplantation, these insulin-secreting cells In 2001, the company raised around A 40 are able to normalize blood glucose levels of million from prominent investors in one of the diabetic mice and protect the animals from largest German financing rounds of that year hyperglycemic episodes. DeveloGen is now lead by TVM and Dresdner Kleinwort Capital. actively pursuing a drug discovery programme Type 2 diabetes, obesity and metabolic with the goal to find small molecules which syndrome are multifactorial diseases, which function as activators of Pax4. call for innovative approaches for the DeveloGen has received supporting grants identification of novel drug targets. DeveloGen from the German Ministry of Education and carries out »phenotype-first« screens for disease Science, the Ministry of Science of the State of specific targets to develop new drugs for the Lower Saxony and the European Union. The treatment of these diseases. In 2003, company is working together with leading DeveloGen entered into a drug discovery research institutes in Europe and the USA. All partnership with Evotec OAI. The partnership technologies and products developed so far creates an integrated venture combining are extensively protected by international DeveloGen’s pipeline of over 200 primary patents and exclusive licenses. candidates and 30 validated targets as well as In November 2003, DeveloGen announced its its know-how in pharmacology, metabolic intention to merge with Peptor Ltd. a biophar- diseases, and assay development with Evotec maceutical company based in Israel. The OAI’s competence ranging from assay merger is subject to shareholders’ approval development and screening all the way and is expected to close within the first half of through to medicinal chemistry and drug 2004. The merger will create an integrated manufacture. biopharmaceutical company with a deep DeveloGen’s approach for the treatment of clinical, preclinical and discovery pipeline of type 1 diabetes follows the concept of medicines to treat metabolic diseases. The regenerative medicine and is focused on merged entity’s lead product, DiaPep277, is in developmental control genes specifying phase II clinical trials for type 1 diabetes. tissue regeneration. The programme is based on the scientific work of Professor Peter Gruss, a DeveloGen co-founder, and was awarded the German Prize for Technology and Innovation by the www.develogen.de

70 Epigenomics Berlin Epigenomics is one of the largest German November 1998 after Alexander Olek’s PhD- private biotechnology companies with 143 thesis at the Max-Planck-Institute for staff in Berlin and a wholly-owned subsidiary Molecular Genetics in Berlin, during which he in Seattle, USA. In 2003, revenues were over filed the basic patent for the work of A 10 million. Epigenomics. Four colleagues joined him in the founder team, an interdisciplinary group In a partnership with Swiss company Roche, with the vision of fighting cancer and other the firm develops novel products for diseases using totally new means. The key lies diagnosis, early detection and better in a novel level of information, DNA- treatment prognosis for cancer. So far, more methylation: a small methyl group can than A 56 million of venture capital have naturally be attached to one of the four been raised. The company was founded in building blocks of DNA. This entails a silencing of unneeded genes even in the healthy organ, because the methyl group stops transcription factors from binding. The pattern of methylated cytosines tells which tissue a cell belongs to, but even diseases have their own characteristic methylation pattern. Epigenomics AG exploits this fact to identify disease, mainly cancer, in very early stages, when the chances of successful treatment are highest.

In addition, Epigenomics together with pharma companies AstraZeneca and Wyeth Pharmaceuticals as well as Roche develops pharmacodiagnostic products: ideally, a patient in the future will be prescribed a drug only if he benefits from it. Discussions with other diagnostic and pharma companies are underway and will lead to further collaborations.

www.epigenomics.com

71 Biotech success stories

Evotec OAI Hamburg Company Profile Our Offering:

Evotec OAI has established itself as the - Assay development partner of choice for drug discovery and - Experiences in various target classes (GPCR, development services for pharmaceutical and kinases, ion channels) biotechnology companies worldwide, - Screening (MTS, HTS, uHTS and virtual) maintaining its leadership role through - Compound libraries (focused, synthesised, innovation and unmatched customer service. natural, virtual) The Company’s business strategy is clearly - Computational chemistry focused on drug discovery. It has established - Structural biology the most comprehensive technology platform - Medicinal chemistry and skills that integrate its world-class biology - Analytical chemistry and chemistry capabilities. Evotec OAI - ADMET platform leverages this discovery engine by providing - Process research & assay development and screening through to development compound optimisation and drug - Scale up and manufacturing manufacturing services, to a broad and well- according to cGMP standards established network of customers. In addition, - Formulation the company engages in selected discovery - Quality and regulation support programmes itself to develop drug candidates for early out-licensing. Evotec OAI’s Evotec OAI and its subsidiaries instrument and technology business is now work closely together with successfully handled by its affiliate, Evotec universities and other research Technologies. institutions on future-orientated topics. This research resulted in several projects initiated Over the last 10 years we have successfully and financed by the BMBF - in particular, in completed more than 1,200 projects for over the area of biotechnology and 150 companies including Amgen, Elixir, nanotechnology. GlaxoSmithKline, Merck, Novartis, Pfizer, Serono and Vertex. Several cooperations have Year of incorporation: 1993 been expanded and / or extended. As a result, Founders: Dr Ulrich Aldag, Dr Karsten we have identified four drug candidates for Henco, Prof Freimut Leidenberger, our partners, which are currently in Phase I Prof Heinrich Schulte, Prof Manfred Eigen of clinical trials. and other scientists IPO: 1999 Turnover 2003: A 77 million Number of employees: > 640 www.evotecoai.com

72 GPC Biotech Martinsried anticancer programmes in development include a monoclonal antibody and a cell cycle inhibitor. The company is leveraging its drug discovery technologies to elucidate the mechanisms-of-action of drug candidates and to support the growth of its drug pipeline. The company has formed successful alliances with a number of pharmaceutical and biotechnology firms. For example, the company has a multi-year alliance with ALTANA Pharma AG to establish the ALTANA Research Institute in the U.S., which provides GPC Biotech with committed revenues until 2007.

The company was founded in 1997 as a spin-off of the Max Planck Institute for Molecular Genetics in Berlin. Since May 2000, GPC Biotech has been listed on the Frankfurt Stock Exchange. The company is part of the TecDAX index, which includes the 30 largest companies of the Deutsche Boerse’s technology segment. The company’s market GPC Biotech AG is a biotechnology company capitalization was A 318 million by the end discovering and developing new anticancer of February 2004. GPC Biotech has drugs. The company’s lead product candidate approximately 180 employees, around half - satraplatin - is currently in a Phase 3 of whom work in the U.S. GPC Biotech AG registrational trial as a second-line is headquartered in Martinsried/Munich chemotherapy treatment in hormone- (Germany). The company’s wholly owned refractory prostate cancer primarily in the U.S. subsidiary has research sites in Waltham, U.S. and Europe, following successful Massachusetts and Princeton, New Jersey. completion of a Special Protocol Assessment by the U.S. FDA and receipt of a Scientific Advice letter from the European regulatory authority, EMEA. The FDA has also granted fast track designation to satraplatin for this indication. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. Other www.gpc-biotech.com

73 Biotech success stories

Jerini Berlin Jerini AG is a drug discovery technology development. In January 2000 and development company Jerini concluded its first financing round based in Berlin, Germany. The (A 4.6 million) to support the company’s company was founded 1994 transition from a tool to a drug discovery as a spin-off from the Medical company. The second private financing round Faculty (Charité) Humboldt (A 20 million) was closed in October 2001. University Berlin. Jerini Jerini’s investor base includes 3i, TVM, successfully operates on the Polytechnos, Sanders Morris Harris, bmp AG, basis of a dual business model that is tbg and IBB Bet.GmbH. supported by two independent units, Jerini Pharmaceuticals and Jerini Peptide Jerini has currently 90 employees and is Technologies (JPT). managed by a team of industry professionals, combining commercial and scientific Jerini Pharmaceuticals discovers and develops experience: Prof. Dr. Jens Schneider-Mergener, drugs applying its proprietary Peptides-To- founder and CEO, Dr. Jochen Knolle, CSO and Drugs (P2D) platform. P2D enables Jerini to Head of R&D (formerly VP AXYS address difficult targets not amenable to Pharmaceuticals and Hoechst/HMR), conventional drug discovery approaches. In Dr. Adi Hoess, CBO (formerly VP Business 2006 the company plans to launch its first Development Morphosys) and Berndt Modig drug product in the indication angioedema. as CFO (formerly CFO Surplex AG). JPT (Jerini Peptide Technologies) is a leading supplier of innovative peptide-based services and products for international pharmaceutical and biotechnological companies as well as for research institutes. JPT is generating profits which support the Jerini Pharmaceuticals business. Jerini has ongoing collaborations with pharmaceutical companies such as Bayer, Baxter and Merck KGaA.

Jerini has started its operations without venture capital and generated revenues from the beginning to support the expansion of the company and its www.jerini.de

74 MediGene Martinsried MediGene AG is a publicly quoted the company founders. Since June 2000, biotechnology company with its headquarters MediGene has been publicly quoted on the located in Martinsried, Germany, and a Frankfurt stock exchange (Prime Standard). subsidiary in San Diego, USA. MediGene has In March 2004, the company announced a the most mature drug development pipeline capital increase of about 20 % by issue of in the German biotech industry and possesses new shares and convertible bonds. At the innovative platform technologies. beginning of 2004, MediGene had 112 employees. With Eligard® for the treatment of prostate cancer, MediGene is the first German biotech MediGene’s most recent success was the company with an approved drug on the verge approval of the anti-cancer drug Eligard® and of market launch. Apart from that, several the conclusion of a marketing partnership drug candidates are currently undergoing clinical development. MediGene’s core competence is research and development of novel approaches for the treatment of various tumor diseases. Thus MediGene focuses on indications of high medical need and great economic opportunities.

It is MediGene’s strategy to integrate all core divisions of a biopharmaceutical company from research and development to commerci- alization of drugs. The revenues from drug sales as well as from marketing and development partnerships shall help to finance the development of other drugs and with the pharmaceuticals group Yamanouchi, to reach break-even. one of the leading companies in the European urology market. MediGene expects MediGene was founded by three professors to make significant progress by the market and a manager from the pharmaceuticals launch of its first drug Eligard®, by the industry in Martinsried in 1994, as a spin-off completion of the final clinical trial (phase 3) of the Munich gene centre. Besides the Chief of MediGene’s Polyphenon® E Ointment to Executive Officer Dr. Peter Heinrich, the treat genital tumors, and by the initiation of Chairman of the Supervisory Board, Prof. Dr. a clinical trial (phase 1/2) of the substance Ernst-Ludwig Winnacker, President of the NV1020 to treat liver metastases. Deutsche Forschungsgemeinschaft DFG (German Research Foundation) are among www.medigene.de

75 Biotech success stories

MorphoSys Martinsried zation and licensing of the HuCAL® technology, the company’s business model also includes building a pipeline with its own antibody products. In this connection, MorphoSys is concentrating on the indications of inflammation and cancer. MorphoSys aims to find suitable partners for the clinical development of these medicines.

The company was founded in 1992 by, amongst others, Dr. Simon E. Moroney, the current Chief Executive Officer, and Professor MorphoSys AG is one of the world’s leading Andreas Plückthun. The company’s own biotechnology companies focusing on technology is based on the research findings antibodies. MorphoSys develops fully human obtained by Professor Plückthun while at the antibodies which are suitable for research Max-Planck Institute for Biochemistry and and diagnostics and to treat diseases. The which have been successfully translated into a company has developed HuCAL® (Human commercial principle. During his career, Dr. Combinatorial Antibody Library), a technolo- Moroney has held research posts at the gically unique antibody library which is home Universities of Cambridge and British to more than 12 billion different, fully human Columbia and at the ETH in Zurich. He also antibodies. The library’s outstanding feature worked at the Harvard Medical School and is its ability to optimize, meaning to tailor the for the American company ImmunoGen antibodies precisely to the respective where he developed therapeutic antibodies. requirements and bind their target molecule To set up the company, the founders acquired with a high affinity. approximately A 550,000 in seed capital from the London-based investment company, Korda Numerous partners such as Schering, Bayer, & Co., tbg Technologie- Centocor/Johnson & Johnson, Pfizer and Beteiligungsgesellschaft mbH in Bonn and Roche are successfully using Technostart in Stuttgart. Until its IPO in HuCAL® technology. In 2003, March 1999, MorphoSys had acquired venture the company achieved a capital and sponsorship money of more than positive EBITDA for the first A 20 million. MorphoSys is the first German time (EBITDA - Earning before biopharmaceutical company to be floated on Interest, Taxes, Depreciation the stock exchange and is currently listed in and Amortization) excluding the Prime Standard of Deutsche Börse. Stock-Based Compensation. In addition to the commerciali- www.morphosys.com

76 Paion Aachen Company profile: PAION GmbH, a biopharma- stroke onset. Today only 2-3% of all patients ceutical company based in Aachen, Germany, worldwide are being treated. The drug is also was founded in 2000 by its Managing being tested in a Phase II study in pulmonary Directors Drs Wolfgang and Mariola Söhngen. embolism. The company is specialised in the develop- ment of innovative therapeutic products for PAION plans to establish a portfolio of stroke the treatment of stroke. An experienced drugs with own and in-licensed development international management team and the projects, the next own product being in support of leading investors are the basis for preclinical tests. rapid growth and the fulfilment of PAION’s vision to become the „PAIONeer in Stroke“. Financing & Business Strategy: PAION aims to be a leading biopharma- ceutical company by establishing itself as the preferred partner for the (co-)development of clinical products in the area of stroke and related diseases. PAION has comprehensive and proven clinical development capabilities including regulatory affairs, assured product manufacturing capacities and know-how. PAION’s revenue stream will include milestone payments and royalties from licensing Products: PAION’s lead product, Desmoteplase, agreements. To date, PAION has raised a total is a genetically engineered version of a blood of A 41.4 million from an international clot dissolving protein from the saliva of the consortium of venture capital groups, banks vampire bat Desmodus rotundus. PAION has and private investors. This financial backing successfully completed its Phase II study of is leveraged by the addition of state and Desmoteplase and aims at getting an federal, project related research approval for Desmoteplase for the treatment grants, to a value of A 5.5 million. of acute ischaemic stroke up to 9 hours after www.paion.de

77 Biotech success stories

Qiagen Hilden QIAGEN is the world’s leading provider of innovative enabling technologies and products for separating and purifying nucleic acids (DNA and RNA) - the genetic information of life. Founded by Dr. Metin Netherland, Australia and Canada, and Colpan, Dr. Carsten Henco and Dr. Juergen employs approximately 1,600 people Schumacher as a spin-off of the Heinrich- worldwide. QIAGEN’s proprietary products are Heine-University, Dusseldorf in sold in more than 42 countries throughout 1984, the Company has the world to academic research markets and developed and marketed a to leading pharmaceutical and biotechnology broad range of proprietary companies. QIAGEN has a 18-year history of products for academic and significant growth. Since 1999, the company industrial life science research has achieved a compound annual net sales markets. growth rate of approximately 22% and net income growth rate of approximately 35%. In recent years, QIAGEN expanded its product QIAGEN’s common shares are traded on portfolio targeting life science research and Nasdaq (QGENF) and on the TecDax of new commercial markets, e.g. genomics, Deutsche Boerse, Frankfurt (QIA, WPKN gene-based drug discovery, nucleic acid-based 901262). Further information on QIAGEN can molecular diagnostics, genetic vaccination, be found at www.QIAGEN.com. and gene therapy. QIAGEN’s comprehensive portfolio of proprietary enabling technologies for separating, purifying, and handling nucleic acids places it firmly at the vanguard of these rapidly growing commercial markets. Because of deep knowledge and experience in the separation and purification of nucleic acids, a broad range of focused technologies, a strong brand awareness, experienced and highly-motivated employees, and a traditional orientation towards innovation allowed to build up a leading position in a research market on which most of the industries base.

QIAGEN N.V., a Netherlands holding company, has subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Norway, the www.qiagen.com

78 Rentschler Laupheim Rentschler Biotechnologie GmbH is an independent biotechnology company of the Rentschler group which is based in Laupheim, Baden Württemberg. great success with an annual increase in turn Rentschler Biotechnologie has over thirty over of over 20%. The forecast for 2004 is for years experience as a pioneering company a turnover of around A 27 million. which began in the 1970’s with the We employ over 230 highly qualified development and licensing of the world’s first specialists who work together to ensure an natural interferon beta. At the end of the efficient and secure product development 1980’s the first license of recombinant from gene to market place. gamma interferon followed. Based on these many years of experience and As one of the few companies in its field expertise in 1997 the concentration of all Rentschler Biotechnologie GmbH offers its business activities on integrated service for partners a complete service from Molecular the order of development and production of Biology to the licensing of the finished biopharmaceutical drugs followed. product. In order to secure Rentschler Biotechnologie’s Our broadly based work spectrum includes: leading position we have specialised in the - Molecular Biology growth area of recombinant proteins - Active Ingredient Development and produced in mammalian cell cultures. Production - Pharmaceutical Production In order to cope with the strength and - Analytics and Quality Control growing demand around A 20 million - Clinical Research between 2001 and 2003 was invested in - Regulatory Affairs additional development and production - Quality Assurance facilities. To support the GMP-Production we now have Our work in the above areas is carried out at our disposal six modern state-of-the-art within the following guidelines: GMP, GLP high technology suites. and GCP are certified by the EMEA and the FDA. This places Rentschler Bio- Rentschler Biotechnologie GmbH provides a technologie GmbH inside complete tailor made service which promises the top ten companies to be fast and reliable. As a result this will world-wide in its field. provide a general reduction in costs, time scales and co-ordination complexity. Rentschler Biotechnologie GmbH has experienced www.rentschler.de

79 Biotech success stories

Scienion Berlin SCIENION AG is a biotechnology company Ulcerosa and Morbus Crohn. focused on high-quality BioChip products, Research into the development of platform hardware and services and offers complete technologies for functional proteome analysis solutions in the field of parallel bioanalysis. is the focus of a joint project in the German Customers are pharma and biotech National Genome Research Net (NGFN). companies as well as academic research Founded in December 2000 as a spin-off from institutions. the Max-Planck-Institute for Molecular One of the many highlights was the Genetics the Berlin-based company with 26 successful launch of a flexible modular employees shows increasing revenues. dispensing system for ultra low level liquid In the year of foundation Scienion was handling. The sciFLEXARRAYER (see figure) awarded with the „Innovationspreis Berlin- transports samples - DNA, proteins or cells - Brandenburg“. Scienion with its management with precisely defined volumes at defined locations onto carriers. In the business area biochips Scienion focuses on the development of customized microarrays for human genome research and genome research on microorganisms. Offering complete solutions Scienion supports customers with comprehensive services in the field of microarrays.

In order to enable better diagnoses and therapies Scienion is engaged in various research projects, some of them funded by the German Federal Ministry of Education and Research. As part of the BioProfile emphasis on the Nutrigenomics Research team of Dr Holger Eickhoff and Dr Alan Berlin-Brandenburg Scienion started the Bullock wants to pave the way for project „Obesity-Chip“ together with partners personalized medicine. Scienion’s platform from the Charité and the Fraunhofer Institute technologies and the expertise of the highly for Biomedical Engineering. The intention of qualified staff allow the development of the joint project is the chip-based market-oriented systems for diagnostics, identification and analysis of the genetically allowing in turn individual therapies and based factors of obesity. therapy control to be recommended. In another joint project Scienion’s chip Main investors are 3i Group, PEPPERMINT. technology is used to investigate the genetic Financial Partners and IBB factors of inflammatory diseases like Colitis Beteiligungsgesellschaft. www.scienion.de

80 SunGene Gatersleben

enabling technologies allowing the transfer of minimal transgene sequences for gene expression in a highly specific manner. One example is our promoter portfolio for the tissue and stage specific expression of genes in crop plants. SunGene holds the exclusive rights on more SunGene GmbH & Co. KGaA is a R&D than 50 patent applications. company in the field of plant biotechnology. SunGene has established collaborations or It belongs to the international research contract relations with numerous inter- platform of BASF Plant Science GmbH. national academic institutions, with plant SunGene has a highly qualified staff of more breeders and ‘life science’ companies. than 60 employees. SunGene applies modern biotechnology to deliver improved crop plants for plant breeders, farmers and end users. The main focus is on traits leading to a higher nutritional value with the emphasis on valuable plant metabolites such as vitamins, carotenoids, or flavonoids. In order to increase the content of plant metabolites, an integrated gene identification and metabolic engineering platform has been developed. One exemplary product candidate generated within this platform is vitamin E in plant oil: SunGene has identified genes which upon expression in crop plants lead to a stable and substantial increase of the vitamin E content in rapeseed oil. Further product candidates are currently being developed on SunGene’s R&D platform. In addition, SunGene has developed comprehensive technologies for high throughput crop plant transformation and www.sungene.de

81 Biotech success stories

Teraklin Rostock The company TERAKLIN AG is active in the University, where a blood purification system field of extracorporeal liver support with its was developed by Dr Steffen Mitzner and Dr MARS® Therapy (Molecular Adsorbents Jan Stange in 1990. In 1991, the Federal Recirculating System). It is the world market Ministry of Research and Education provided leader in this field. The liver dialysis MARS® funding resources of two million DM. In takes over the liver’s detoxification function conjunction with a chemist, Dr Stephan outside the body, being implemented both in Aldinger, and a physicist, Dr Walter Gerike, cases of acute liver failure as well as for acute Mitzner and Stange were able to develop the deterioration of chronic liver disease. Support liver support system MARS® during the years of hepatic detoxification allows the organ to that followed. regenerate itself or to serve as a bridge until liver transplant. More than 4000 patients have The companies TERAKLIN Medizinprodukte currently been treated with MARS® Therapy GmbH (concerned chiefly with equipment worldwide. technology) and Biopure Medizinprodukte The origins of the company go back to clinical GmbH (focussing on disposables) were research work carried out at Rostock established in 1997, giving rise to TERAKLIN AG in 1998. In order to increase the spectrum of services, the company merged with Celltect GmbH in 2001, a company specialising in the developing a therapy of life-threatening cases of sepsis. Today, TERAKLIN is represented by subsidiaries in France, Great Britain, Spain and USA, a branch in China as well as distribution partners in more than 30 countries. TERAKLIN AG’s head office is in Rostock, where Research & Development as well as Production are also located. The Sales and Marketing divisions have been established in Hamburg. The board of management is composed of two members, responsible for Administration/Finance, Quality Management and Production (Beatrice König-Stölzel, CEO) and Marketing, Sales, Clinical Affairs and Research & Development (Dr Stephan Aldinger).

www.teraklin.com

82 Wilex München Patient Focused Cancer Therapies Antibody Rencarex® against RCC in Phase Wilex, based in Munich, is a leading III Study European biopharmaceutical company Wilex’s most advanced compound is the focusing on the development of novel chimeric antibody Rencarex® for the targeted cancer therapies for the treatment of treatment of Renal Cell Carcinoma (RCC). various tumors including renal cell cancer, Rencarex® has completed Phase II trials in breast, gastric, and colon cancer. Therapies RCC in which it showed strong enhancement are tailored to the individual needs of patient of patient long term survival together with groups in order to provide effective and well an excellent safety profile. In the first half of tolerated treatment. 2004, Wilex plans to start an international Wilex was founded in late 1997 by clinical pivotal Phase III study with Rencarex® in RCC oncologists from the Technical University of patients with the goal of receiving marketing Munich. The Company has raised A 38.5 approval. RCC is the 10th most common form million (to date) in venture capital and has of cancer in the US and Europe. To date, currently 42 employees. Chief Executive is there is no safe and well tolerated therapy Prof. Olaf G. Wilhelm, M.D., formerly Senior available for this indication. Physician at the Technical University of Munich. Chairman of the Supervisory Board is Inhibiting Tumor Cell Invasion and David Ebsworth, Ph.D., formerly President of Metastasis the global Pharmaceutical Division of Bayer. Wilex’s „uPA programme“ is one of the best Within a few years, Wilex has established one validated approaches in cancer therapy to of the most advanced anti-cancer develop- specifically block tumor cell invasion and ment portfolios in the German biotech metastasis in solid tumors. The small industry. The Company has currently three molecule compound WX-UK1 is the first uPA compounds in clinical trials and five in pre- inhibitor in clinical trials worldwide. In clinic and research. Wilex has two thera- September 2003, Wilex was awarded the peutic platforms: antibody-based and small Biotechnology Clinical Partnership Award molecule-based therapies. worth USD 3.9 million from the Breast Cancer Research Programme of the US Department of Defense. The grant will be used to fund two clinical trials with WX-UK1 in breast cancer patients in the US. The goal of this award is to accelerate the clinical development of novel compounds with the potential to revolutionize breast cancer therapeutics or chemoprevention.

For further information please visit: www.wilex.com

83 Interim report

Interim Report on Biotechnology Funding

As a result of the Federal Government’s These companies are primarily located in the intensified commitment in the field of biotechnology regions (25 in total) (Figure 5). biotechnology, Germany has managed to catch These are clusters characterized by the up with the global developments of this key integration of existing strengths, optimum technology in recent years. boundary conditions for research, innovations and investments, and accelerated commerciali- In addition to strengthening excellent basic zation. research (Figures 1-3), a breakthrough has been achieved in the commercialization of Since 1998, biotechnology has been supported biotechnology (Figures 4-5) by means of with A 1.03 billion within the framework of targeted support tools (e.g. region compe- project funding by the German Federal titions). Even if there is still an inadequacy Ministry of Education and Research (BMBF), of gap and the industry has not yet reached the which A 750 million was made available for maturity of businesses as e.g. in the United funding research and development projects at Kingdom, the German biotechnology industry academic institutions and A 281 million was occupies the number one position in Europe spent on support for research and concerning the number of biotechnology development projects implemented by small companies with a potential for development. and middle sized enterprises. Total project

Non-university research Training and research in biotech- Training in biotechnology at univer- institutions of biosciences nology at scientific universities sities of applied sciences in Germany

Flensburg Kiel

Rostock Rostock Lübeck Hamburg Hamburg Emden Hamburg Bremen Oldenburg Bremen Berlin Bremen Berlin Berlin Hannover Hannover Hannover Potsdam Osnabrück Braunschweig Braunschweig Lemgo Wildau Münster Clausthal Dortmund Magdeburg Bielefeld Münster Gelsenkirchen Köthen Göttingen Halle Halle Dortmund Düsseldorf Bochum Leipzig Iserlohn Göttingen Dresden Essen Zittau Düsseldorf Kassel Dresden Köln Jena Jena Leipzig Köln Aachen Fulda Jena Lausitz Aachen Marburg Bonn Giessen Bonn Giessen Giessen Bayreuth Mainz Bingen Frankfurt Frankfurt Frankfurt Würzburg Saarbrücken Kaiserslautern Darmstadt Darmstadt Saarbrücken Heidelberg Heidelberg Mannheim Nürnberg Karlsruhe Regensburg Stuttgart Aalen Karlsruhe Stuttgart Tübingen Tübingen Reutlingen Freising Freiburg München Ulm München München Freiburg Furtwangen Konstanz

Institute of the Helmholtz Association (HGF) Institute of the Gottfried Wilhelm Leibniz Association of German Research Centres (WGL) Locations for studies with focus on biotechnology Max Planck Institute Locations for studies with predominantly techn. orientation Federal institutions with R&D tasks Fraunhofer Institute Locations for studies with predominantly molecular-biological orientation Fig. 1, source: ISB 2004 Fig. 2-3, source: VdBiol, ISB 2003, www.vdbiol.de/studium

84 Biotech companies in Germany Biotech companies and employees in the BioRegions 700

600

500

400

300

200

100

0 1995 1996 1997 1998 1999 2000 2001 2002 2003

Note: This includes core biotech firms and also large enterprises with core business in the field of biotechnology (e.g. Boehringer Ingelheim in Biberach, Roche in Penzberg, Rentschler in Laupheim, Strahtmann in Hamburg). The persons employed in the biotechnology divisions of large chemicals and pharmaceuticals companies, however, could not be reliably determined and were therefore not included.

Fig. 4, source: ISB 2004 Fig. 5, source: ISB 2004

costs were in the range of A 1.35 billion, i.e. Munich (see Figure 10), but smaller regions almost 1/4 of the costs (about A 320 million) also demonstrate that they are aware of the were covered by private capital (Figure 8). importance of biotechnology as an industry of the future. In these regions, up to 40 % of the The goals of the different funding priorities of expenditure on research and development is the BMBF are official precaution (e.g. preven- financed by private capital. tion by proper nutrition, TSE diagnosis, safety research), the expansion of basic innovations Biotechnology companies have been (genome research, neurobiology, system increasingly funded since 1998 (Figure 11). The biology), technological development (bioinfor- main portion of funds has flown into the large matics, proteome research, nanobiotechnology BioRegions in the past, where the dynamic etc.), measures to improve technology transfer innovation process has taken place particularly and commercialize biotechnology (BioRegio, rapidly and has significantly stimulated BioProfiles, Bio-Chance) as well as support for technology development. In this period, 298 young scientists (Figure 9). start-ups and settlements have been recorded in the model regions (46 around Jena, 57 in The greatest dynamic especially with respect the Rhine-Neckar triangle, 80 in the Rhineland to private fund raising was achieved in the and 115 in the Munich region). A total of A model regions of Heidelberg, Cologne and 1,020 million of venture capital was mobilized

85 Interim report

Fields of activity of the biotechnology Biotech companies in Germany - companies in Germany number of employees per company

1999 Pharma 9% 7% 44% Diagnostics 40%

Supply & Service 2001 8% Contract production 10% 38%

DNA Analysis 44% 2003 Bioinformatics

Proteomics < 10 7% 11-50 10% Ag biotech 51-100 35% >100 Bioinstruments 48%

Environmental

0 50 100150200250300350 Companies

Note: The companies were allowed to specified several business areas Fig. 6, source: ISB 2004 Fig. 7, source: ISB 2004

and a seed capital fund of more than A 176 Relative to the total number of biotechnology million launched. firms, Europe has meanwhile caught up with Increased support for the commercialization of North America (USA and Canada) recording biotechnology since the mid-nineties initiated approx 1900 companies (Ernst&Young Global a development which has led to a rapid Biotech Report 2003). growth of the German biotechnology industry also against the background of positive The growth of German biotechnology compa- economic and financial boundary conditions. nies and reaching a critical mass, however, will According to a recent survey by the be decisive for the future development of the Information Secretariat for Biotechnology (ISB biotechnology industry especially in Germany. 2004), there are at present just about 600 It is not the number of companies, but rather biotechnology firms in Germany. the establishment of strong firms of global significance that will be pave the way in the The ranking of the German biotechnology next few years for promising innovations in cluster in an international comparison was medicine and health, environment, nutrition first studied by the Boston Consulting Group in and agriculture as well as industrial produc- early 2001. According to this study, the tion. By means of new support measures (e.g. American clusters of San Francisco and Boston „Bio-ChancePLUS“) the BMBF now attends the were leading worldwide with respect to the consolidation and growth process of young number of companies, number of employees biotechnology companies currently at the per company and number of listed companies. period of growth, in addition to supporting

86 Project funding by BMBF in the field of Project funding by BMBF in the field of biotechnology according to years in million B biotechnology according to thematic priorities

200,0

180,0 300,0 160,0

own contribution 250,0 140,0 funding

120,0 other 200,0 grants to young researchers social security payments €m 100,0 structural investments €m 150,0 platform technologies 80,0 basic innovations

100,0 60,0

40,0 50,0 20,0

0,0 0,0 1998 1999 2000 2001 2002 2003 1998 1999 2000 2001 2002 2003

Fig. 8, source: PTJ 2004 Fig. 9, source: PTJ 2004

The increase of funds in 2001 is explained by the provision of UMTS funds used for building up the National Genome Research Network.

start-ups, and at the same time provide room and also other companies aiming to utilize for new technology developments and for biotechnological processes will serve to networking and exploitation strategies. combine scientific, technical and financial strengths and resources so as to accelerate Strategic alliances, cooperations and company product development. networks involving young biotechnology firms

Project funding by BMBF in the BioRegions Project funding by BMBF in the field of in the field of biotechnology biotechnology for companies

250 100

90 own contribution 200 80

support for industry 70

support for industry 150 60 own contribution support for R&D €m institutions €m 50

100 40

30

50 20

10

0 0 BioTOP Berlin-Brandenburg Bio-M BioRegion Rhine-Neckar triangle BioRegioN + BioProfil (BioRiver)BioRegion Cologne/Düsseldorf BioRegion STERN BIO Central Germany BioTec Frankfurt/Rhine Main BioRegio Jena BioMedTec Franken Biotechnology Initiative Marburg BioRegion (SH) North BioRegion HH North BioRegio Freiburg (Biovalley) Bio-Tech-Region OWL BioRegion RP Biosaxony BioRegion eastern Ruhr district (BioIndustry) BioRegion Meuse Rhine Triangle BioRegion Bremen Biotech Region Münster Biocon Valley NanoBioNet BioRegio Ulm BioPark Regensburg Bio-M BioRegion Rhine-Neckar triangle BioTOP Berlin-Brandenburg BioRegioN + BioProfil (BioRiver)BioRegion Cologne/Düsseldorf BioTec Frankfurt/Rhine Main BioRegion STERN BioRegio Jena BIO Central Germany BioRegion RP BioRegio Freiburg (Biovalley) BioRegion HH North BioRegion Meuse Rhine Triangle BioRegion (SH) North BioconValley Biotechnology Initiative Marburg BioRegion Bremen Biosaxony Bio-Tech-Region OWL BioRegion eastern Ruhr district (BioIndustry) BioPark Regensburg BioMedTec Franken NanoBioNet Biotech Region Münster BioRegio Ulm

Fig. 10, source: PTJ 2004 Fig. 11, source: PTJ 2004

87

This publication is distributed free of charge by the German Federal Ministry of Education and Research as part of its public relations work. It is not intended for commercial sale. It may not be used by political parties, candidates or electoral assistants during an election cam- paign. This applies to parliamentary, state assembly and local govern- ment elections as well as to elections to the European Parliament. In particular the distribution of this publication at election events and at the information stands of political parties, as well as the insertion, printing or affixing of party political information, are regarded as Impressum improper use. The distribution of this publication to third parties as a Published by form of campaign publicity is also prohibited. Bundesministerium Regardless of how recipients came into possession of this publication für Bildung und Forschung / and how many copies of it they may have, it may not be used in a man- Federal Ministry of Education and Research (BMBF) ner that may be considered as showing the partisanship of the Federal Publications and Website Division Government in favour of individual political groups, even if not within 11055 Berlin the context of an upcoming election. Orders In writing to the publisher Postfach 30 02 35 53182 Bonn

Or by Phone: +49 (0) 1805 - 262 302 Fax: +49 (0) 1805 - 262 303 (0.12 Euro/min.)

E-Mail: [email protected] Internet: http://www.bmbf.de

Contributions The Bioregions and companies are responsible for the texts of their contributions. If not stated otherwise they also hold the copyrights of the photographs and graphics therein. Photograph on cover: Merck KGaA

Printed by Druckerei Bonn&Fries 57074 Siegen

Berlin 2004

Printed on recycled paper Strong impulses for national technological development

BioRegions in Germany Strong impulses for national technological development BioRegions in Germany –

RESEARCH The Germany of Tomorrow